Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
48.1 /100
Rank 13 out of 27 Sectors -
Advance/Decline
294/360
-
No. of Companies654
-
Avg. Market Cap8,001
-
Price to Earning Ratio7.45
-
Price to Earning Growth Ratio0.75
-
Price to Book Ratio44.66
-
Return on Equity47.36
-
Return on Capital Employed-
-
Return on Assets10.82
-
Dividend yield 1 year %0.75 %
-
Net Profit Growth Annual YoY %-11.91 %
-
Net Profit Growth Qtr YoY %-62.59 %
-
Net Profit Growth Qtr QoQ %-69.97 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
388,966.0
|
220.1
|
L
 -1.8%
H
219
225.1
|
L
 -4.0%
H
217.9
237.0
|
L
 -1.3%
H
217.9
237.0
|
L
 -4.6%
H
211.7
239.3
|
L
 23.3%
H
164.4
244.8
|
L
 36.1%
H
131.0
244.8
|
L
 105.2%
H
101.8
244.8
|
L
 295.5%
H
50.7
244.8
|
| Adc Therapeutics SA |
|
453.4
|
3.7
|
L
 2.5%
H
3.5
3.8
|
L
 4.0%
H
3.4
3.8
|
L
 3.7%
H
3.3
4.3
|
L
 -20.3%
H
2.9
4.8
|
L
 90.6%
H
1.1
4.8
|
L
 0.8%
H
0.4
6.0
|
L
 -88.8%
H
0.4
34.5
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,074.1
|
13.0
|
L
 -1.8%
H
12.9
13.3
|
L
 2.4%
H
12.3
13.5
|
L
 8.3%
H
11.9
13.5
|
L
 26.0%
H
9.6
13.5
|
L
 60.8%
H
6.7
13.5
|
L
 489.1%
H
1.2
13.5
|
L
 171.1%
H
1.2
13.5
|
L
 -66.2%
H
1.2
40.7
|
| Annovis Bio Inc |
|
97.3
|
3.7
|
L
 -6.4%
H
3.7
4.0
|
L
 0.6%
H
3.6
4.1
|
L
 -17.7%
H
3.3
4.6
|
L
 66.8%
H
1.6
5.5
|
L
 -26.6%
H
1.1
5.5
|
L
 -70.2%
H
1.1
23.9
|
L
 -58.4%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,745.5
|
7.4
|
L
 -4.6%
H
7.4
7.9
|
L
 2.8%
H
7.2
8
|
L
 9.0%
H
6.7
8
|
L
 16.0%
H
5.9
8
|
L
 -5.4%
H
4.3
8.7
|
L
 -1.9%
H
4.0
11.5
|
L
 -67.9%
H
4.0
34.8
|
L
 -91.9%
H
4.0
101.4
|
| Bristol-Myers Squibb |
|
113,717.2
|
55.9
|
L
 -0.1%
H
55.6
56.3
|
L
 4.5%
H
52.1
57.0
|
L
 10.3%
H
50.3
57.0
|
L
 25.0%
H
42.5
57.0
|
L
 -1.7%
H
42.5
63.3
|
L
 -21.3%
H
39.4
75.2
|
L
 -10.6%
H
39.4
81.4
|
L
 -12.2%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
680.7
|
13.0
|
L
 -3.0%
H
12.9
13.5
|
L
 3.6%
H
12.4
14.1
|
L
 11.5%
H
11.2
14.1
|
L
 29.1%
H
9.0
14.1
|
L
 29.0%
H
4.0
14.1
|
L
 -1.4%
H
1.4
16.7
|
L
 -86.7%
H
1.4
127.2
|
L
 -61.1%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,661.4
|
23.5
|
L
 1.0%
H
23.1
23.6
|
L
 4.2%
H
22.3
23.9
|
L
 14.9%
H
20.5
23.9
|
L
 16.9%
H
19.5
23.9
|
L
 103.2%
H
8.0
23.9
|
L
 84.2%
H
7.9
23.9
|
L
 -25.2%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
101,639.8
|
50.4
|
L
 0.3%
H
50.4
50.8
|
L
 1.5%
H
48.6
51.5
|
L
 6.6%
H
47.8
51.5
|
L
 16%
H
42.8
51.5
|
L
 49.3%
H
31.7
51.5
|
L
 45.9%
H
31.7
51.5
|
L
 29.1%
H
28.5
51.5
|
L
 25.6%
H
28.5
51.5
|
| Johnson & Johnson |
|
492,435.8
|
204.4
|
L
 -0.7%
H
204.0
206.7
|
L
 -1.4%
H
200.9
209.0
|
L
 2.2%
H
200.2
215.2
|
L
 7.0%
H
184.7
215.2
|
L
 43.7%
H
140.7
215.2
|
L
 16.4%
H
140.7
215.2
|
L
 27.7%
H
140.7
215.2
|
L
 108.2%
H
94.3
215.2
|
| Eli Lilly |
|
951,906.2
|
1,063.6
|
L
 -2.0%
H
1063.0
1104.5
|
L
 -1.6%
H
1033.4
1134.0
|
L
 8.3%
H
977.1
1134.0
|
L
 24.3%
H
783.8
1134.0
|
L
 35.3%
H
623.8
1134.0
|
L
 204.0%
H
302.1
1134.0
|
L
 539.1%
H
177.4
1134.0
|
L
 1209.0%
H
64.2
1134.0
|
| Merck & Company |
|
274,338.0
|
110.5
|
L
 -0.4%
H
110.2
112.5
|
L
 3.8%
H
105.8
112.9
|
L
 14.1%
H
96.5
112.9
|
L
 26.3%
H
82.0
112.9
|
L
 10.7%
H
73.3
112.9
|
L
 0.1%
H
73.3
134.6
|
L
 39.5%
H
68.4
134.6
|
L
 126.8%
H
45.8
134.6
|
| Nuvation Bio Inc (Class A) |
|
2,756.4
|
8.0
|
L
 -4.9%
H
8.0
8.5
|
L
 -6.3%
H
8.0
9.1
|
L
 0.5%
H
7.8
9.8
|
L
 114.4%
H
3.4
9.8
|
L
 167.1%
H
1.5
9.8
|
L
 294.1%
H
1.0
9.8
|
L
 -27.0%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
261,321.0
|
58.8
|
L
 2.6%
H
58.8
60.6
|
L
 12.3%
H
53.4
60.6
|
L
 26.9%
H
47.0
60.6
|
L
 0.2%
H
43.1
60.6
|
L
 -31.3%
H
43.1
93.8
|
L
 -14.3%
H
43.1
148.2
|
L
 67.4%
H
33.3
148.2
|
L
 114.8%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
271,585.8
|
141.5
|
L
 0.1%
H
141.5
142.9
|
L
 2.2%
H
135.6
143.5
|
L
 8.0%
H
130.5
143.5
|
L
 8%
H
121.6
143.5
|
L
 41.2%
H
97.4
143.5
|
L
 57.4%
H
80.0
143.5
|
L
 50.5%
H
74.1
143.5
|
L
 96.3%
H
59.2
143.5
|
| Organon & Co. |
|
2,092.9
|
8.1
|
L
 -1.0%
H
7.9
8.3
|
L
 11.2%
H
7.2
8.5
|
L
 15.8%
H
6.8
8.5
|
L
 -18.9%
H
6.2
9.9
|
L
 -49.7%
H
6.2
17.2
|
L
 -72.8%
H
6.2
32.4
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare Inc |
|
3,085.6
|
64.2
|
L
 0.3%
H
62.9
64.6
|
L
 4.8%
H
60.9
64.6
|
L
 7.1%
H
59.8
64.6
|
L
 2.2%
H
57.3
64.6
|
L
 -13.7%
H
57.3
90.0
|
L
 -3.1%
H
56.0
90.0
|
L
 72.9%
H
36.9
90.0
|
L
 36.3%
H
26.3
90.0
|
| Pfizer |
|
144,871.8
|
25.5
|
L
 0.8%
H
25.2
25.6
|
L
 1.2%
H
25.0
26
|
L
 0.6%
H
24.8
26.7
|
L
 1.0%
H
23.9
26.7
|
L
 -5.1%
H
20.9
27.7
|
L
 -47.3%
H
20.9
48.5
|
L
 -31.4%
H
20.9
61.7
|
L
 -13.2%
H
20.9
61.7
|
| Perrigo Co PLC |
|
2,075.4
|
15.1
|
L
 2.6%
H
14.7
15.1
|
L
 8.6%
H
13.9
15.1
|
L
 13.2%
H
12.7
15.1
|
L
 -30.0%
H
12.2
22.0
|
L
 -39.8%
H
12.2
30.9
|
L
 -58.1%
H
12.2
40.3
|
L
 -66.2%
H
12.2
50.9
|
L
 -89.3%
H
12.2
152.4
|
| Arcus Biosciences Inc |
|
2,599.5
|
21.0
|
L
 -1.6%
H
20.6
21.5
|
L
 -9.8%
H
20.6
23.4
|
L
 -16.2%
H
20.4
26.1
|
L
 38.6%
H
14.3
26.4
|
L
 40.8%
H
6.5
26.4
|
L
 20.0%
H
6.5
26.4
|
L
 -31.9%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,155.8
|
13.4
|
L
 0.4%
H
13.4
13.5
|
L
 -3.3%
H
13.4
14.1
|
L
 -3.0%
H
13.4
14.3
|
L
 -5.4%
H
13.1
15.0
|
L
 -15.2%
H
12.3
16.2
|
L
 26.1%
H
10.2
74.9
|
L
 -6.6%
H
9.6
74.9
|
L
 50.9%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
51,526.4
|
16.3
|
L
 -0.4%
H
16.2
16.4
|
L
 4.4%
H
15.5
16.4
|
L
 14.4%
H
14.2
16.4
|
L
 15.8%
H
13.0
16.4
|
L
 23.2%
H
12.8
16.4
|
L
 4.8%
H
12.6
17.2
|
L
 -10.6%
H
12.3
20.0
|
L
 -33.6%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
36,724.5
|
32.0
|
L
 -1.5%
H
31.8
32.7
|
L
 3.4%
H
30.5
32.9
|
L
 12.1%
H
28.8
32.9
|
L
 59.7%
H
18.8
32.9
|
L
 49.0%
H
12.5
32.9
|
L
 193.9%
H
7.1
32.9
|
L
 196.7%
H
6.8
32.9
|
L
 -49.7%
H
6.1
65.2
|
| Usana Health Sciences Inc |
|
362.9
|
19.9
|
L
 -0.8%
H
19.7
20.4
|
L
 2.1%
H
18.9
20.4
|
L
 -1.1%
H
18.9
21.1
|
L
 -24.4%
H
18.5
24.3
|
L
 -43.2%
H
18.5
38.3
|
L
 -64.7%
H
18.5
69.6
|
L
 -75.1%
H
18.5
107.9
|
L
 -66.6%
H
18.5
138.0
|
| Zoetis (Class A) |
|
56,043.0
|
127.2
|
L
 0.3%
H
126.1
128.4
|
L
 1.0%
H
124.6
131.1
|
L
 9.9%
H
115.6
131.1
|
L
 -11.3%
H
115.3
148.3
|
L
 -22.9%
H
115.3
177.4
|
L
 -13.5%
H
115.3
201.9
|
L
 -24.4%
H
115.3
249.3
|
L
 177.2%
H
38.3
249.3
|
| Biohaven Ltd |
|
1,474.2
|
11.1
|
L
 -2.2%
H
11.0
12.0
|
L
 2.5%
H
9.3
12.1
|
L
 6.0%
H
9.3
12.1
|
L
 -35.5%
H
7.5
18.6
|
L
 -71.6%
H
7.5
44.3
|
L
 -25.7%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
124.4
|
2.6
|
L
 -2.6%
H
2.6
2.7
|
L
 8.2%
H
2.5
2.8
|
L
 2.7%
H
2.2
2.9
|
L
 21.7%
H
1.9
3.8
|
L
 -26.7%
H
1.4
3.8
|
L
 -78.2%
H
1.2
13.5
|
L
 -84.3%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,308.1
|
4.4
|
L
 6.3%
H
4.2
4.5
|
L
 27.4%
H
3.4
4.5
|
L
 18.8%
H
3.3
4.5
|
L
 -26.1%
H
3.3
6.2
|
L
 44.2%
H
1.9
6.5
|
L
 -54.2%
H
1.9
11.4
|
L
 -89.0%
H
1.9
55.2
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
281.3
|
5.2
|
L
 2.0%
H
5.1
5.3
|
L
 -2.3%
H
5.0
5.4
|
L
 -1.0%
H
4.8
5.6
|
L
 -8.3%
H
4
5.7
|
L
 -12.9%
H
3.9
7.5
|
L
 69.6%
H
2.2
9.0
|
L
 -88.2%
H
2.2
94.8
|
L
 -92.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,348.7
|
27.9
|
L
 5.5%
H
26.5
28.2
|
L
 -1.5%
H
25.2
28.5
|
L
 -9.5%
H
25.2
32.6
|
L
 9.0%
H
24.3
32.6
|
L
 46.6%
H
5.5
32.6
|
L
 -6.8%
H
2.2
53.9
|
L
 -45.0%
H
2.2
66
|
L
 -97.1%
H
2.2
1000.1
|
| Acumen Pharma Inc |
|
109.6
|
1.8
|
L
 -2.7%
H
1.7
1.9
|
L
 -10.4%
H
1.7
2.1
|
L
 -7.2%
H
1.7
2.4
|
L
 -19.6%
H
1.5
2.5
|
L
 6.5%
H
0.9
2.5
|
L
 -66.8%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
888.5
|
4.6
|
L
 -0.7%
H
4.6
4.7
|
L
 -3.1%
H
4.6
5
|
L
 3.6%
H
4.4
5.1
|
L
 8.2%
H
4.1
5.1
|
L
 37.9%
H
2.7
5.1
|
L
 73.0%
H
1.7
5.1
|
L
 19.4%
H
1.7
6.5
|
L
 14.9%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
53.0
|
2.2
|
L
 -3.1%
H
2.1
2.3
|
L
 -0.5%
H
2.1
2.4
|
L
 -2.2%
H
2.0
2.5
|
L
 -33.7%
H
2.0
3.3
|
L
 311.3%
H
0.4
5.5
|
L
 -77.8%
H
0.4
10.2
|
L
 -95.6%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
| Acadia Pharma Inc |
|
4,530.7
|
26.8
|
L
 -0.5%
H
26.5
27.2
|
L
 1.9%
H
25.6
27.7
|
L
 -0.4%
H
25.6
28.4
|
L
 29.8%
H
19.7
28.4
|
L
 55.6%
H
13.4
28.4
|
L
 58.8%
H
13.4
33.9
|
L
 -49.6%
H
12.2
55.1
|
L
 -4.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
77.1
|
8.0
|
L
 -0.7%
H
7.9
8.2
|
L
 -9.0%
H
7.9
9.1
|
L
 -6.4%
H
7.4
9.4
|
L
 -45.1%
H
7.4
17.4
|
L
 -46.6%
H
7.2
17.4
|
L
 -93.4%
H
7.2
152.4
|
L
 -96.3%
H
7.2
349.9
|
L
H
7.2
349.9
|
| Achieve Life Sciences Inc |
|
296.0
|
5.6
|
L
 1.7%
H
5.4
5.6
|
L
 11.9%
H
4.9
5.6
|
L
 18.8%
H
4.2
5.6
|
L
 69.5%
H
3.0
5.8
|
L
 58.0%
H
1.8
5.8
|
L
 98.6%
H
1.8
10.3
|
L
 -36.9%
H
1.8
16.1
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
343.0
|
3.4
|
L
 -0.9%
H
3.4
3.6
|
L
 1.5%
H
3.3
3.7
|
L
 34.3%
H
2.5
3.8
|
L
 -2.0%
H
2.5
4
|
L
 21.8%
H
1.4
4
|
L
 57.1%
H
1.4
5.1
|
L
 -41.0%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
3,831.9
|
66.3
|
L
 3.1%
H
64.7
66.8
|
L
 4.6%
H
60.4
66.8
|
L
 -6.5%
H
60.4
74.0
|
L
 -25.0%
H
60.4
94.1
|
L
 -8.3%
H
47.9
94.1
|
L
 110.4%
H
26.3
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Aclaris Therapeutics Inc |
|
286.0
|
2.6
|
L
 -1.5%
H
2.6
2.7
|
L
 -8.3%
H
2.5
2.9
|
L
 -17.8%
H
2.5
3.5
|
L
 35.4%
H
1.7
3.5
|
L
 7.3%
H
1.1
3.5
|
L
 -83.8%
H
0.6
18.5
|
L
 -57.4%
H
0.6
30.4
|
L
 -88.8%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
55.2
|
1.8
|
L
 -9.3%
H
1.8
2.0
|
L
 -28.9%
H
1.8
3.6
|
L
 -29.7%
H
1.8
3.6
|
L
 -10.7%
H
1.7
3.6
|
L
 -71.3%
H
1.1
8
|
L
 -84.8%
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
18.0
|
1.1
|
L
 -2.8%
H
1.1
1.2
|
L
 -8.6%
H
1.1
1.3
|
L
 -13.8%
H
1.0
1.3
|
L
 -16.5%
H
1.0
1.6
|
L
 112%
H
0.4
1.6
|
L
 -51.4%
H
0.4
2.8
|
L
 -96.1%
H
0.4
58.8
|
L
 -98.5%
H
0.4
115
|
| Grace Therapeutics Inc |
|
57.1
|
3.7
|
L
 -2.9%
H
3.7
3.9
|
L
 0.8%
H
3.5
3.9
|
L
 6.3%
H
3.2
3.9
|
L
 22.2%
H
3.0
3.9
|
L
 -12.4%
H
1.8
4.7
|
L
 -9.6%
H
1.7
5.1
|
L
 -86.5%
H
1.7
58.6
|
L
 -95.9%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.9
|
2.9
|
L
 0.3%
H
2.9
3.1
|
L
 6.2%
H
2.7
3.5
|
L
 -30.9%
H
2.4
4.4
|
L
 -60.6%
H
2.4
8.0
|
L
 -80.5%
H
2.4
21
|
L
 -96.6%
H
2.4
176.4
|
L
H
2.4
176.4
|
L
H
2.4
176.4
|
| Adial Pharma Inc |
|
6.7
|
0.2
|
L
 4.4%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -22.6%
H
0.2
0.3
|
L
 -42.9%
H
0.2
0.4
|
L
 -76.5%
H
0.2
1.3
|
L
 -97.4%
H
0.2
15
|
L
 -99.5%
H
0.2
127
|
L
H
0.2
236
|
| Adma Biologics Inc |
|
4,272.1
|
18.0
|
L
 -0.7%
H
17.9
18.2
|
L
 0.4%
H
17.7
19.0
|
L
 -9.3%
H
17.5
20.5
|
L
 21.8%
H
13.8
20.5
|
L
 -3.3%
H
13.5
25.7
|
L
 411.4%
H
2.9
25.7
|
L
 738.8%
H
1.0
25.7
|
L
 151.0%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,406.0
|
15.8
|
L
 -1.3%
H
15.5
16.3
|
L
 -0.9%
H
15.3
17.3
|
L
 6.1%
H
14.9
17.5
|
L
 0.7%
H
13.3
20.8
|
L
 135.6%
H
6.0
20.8
|
L
 82.0%
H
2.3
20.8
|
L
 -73.9%
H
2.3
71.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
1.4
|
0.8
|
L
 -6.0%
H
0.8
0.9
|
L
 -10.2%
H
0.8
1.0
|
L
 -75.1%
H
0.8
3.4
|
L
 -99%
H
0.8
84.4
|
L
 -100.0%
H
0.8
438581.3
|
L
 -100.0%
H
0.8
3453280000
|
L
 -100.0%
H
0.8
10000000000
|
L
H
0.8
10000000000
|
| Agenus Inc |
|
133.0
|
3.9
|
L
 4.3%
H
3.8
4
|
L
 21.1%
H
3.2
4
|
L
 -0.3%
H
3.0
4.1
|
L
 -8%
H
3.0
4.7
|
L
 12.7%
H
1.4
7.3
|
L
 -91.6%
H
1.4
196
|
L
 -93.9%
H
1.4
196
|
L
 -94.7%
H
1.4
196
|
| Agios Pharma Inc |
|
1,656.7
|
28.4
|
L
 0.9%
H
28.0
28.7
|
L
 4.5%
H
26.5
29.4
|
L
 5.8%
H
24.2
30.0
|
L
 -33.0%
H
22.2
46
|
L
 -20.9%
H
22.2
46
|
L
 -2.8%
H
19.8
62.6
|
L
 -38.0%
H
16.8
62.6
|
L
 -45.0%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
123.9
|
30.6
|
L
 1.6%
H
30.4
31.5
|
L
 0.1%
H
28
31.7
|
L
 -9.1%
H
28
35.3
|
L
 44.6%
H
18.1
35.3
|
L
 101.7%
H
13.9
35.3
|
L
 142.6%
H
2.7
35.3
|
L
 -85.0%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Akebia Therapeutics Inc |
|
403.4
|
1.5
|
L
 2.0%
H
1.5
1.5
|
L
 -1.9%
H
1.5
1.6
|
L
 -3.8%
H
1.5
1.7
|
L
 -47.4%
H
1.4
3.2
|
L
 -15.1%
H
1.4
4.1
|
L
 137.5%
H
0.5
4.1
|
L
 -51.0%
H
0.2
5.1
|
L
 -82.1%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
5.4
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 -25.7%
H
0.9
1.7
|
L
 -47.1%
H
0.9
2.4
|
L
 -64.1%
H
0.9
11.7
|
L
 -68.3%
H
0.2
11.7
|
L
 -89.1%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
247.3
|
4.1
|
L
 -1.7%
H
4.0
4.3
|
L
 -12.0%
H
4.0
4.8
|
L
 -14.2%
H
3.9
5.7
|
L
 -27.5%
H
3.9
5.8
|
L
 -19.6%
H
1.1
7.2
|
L
 -35.5%
H
1.1
12.0
|
L
 -60.1%
H
1.1
16.0
|
L
 -39.1%
H
1.1
16.7
|
| Alector Inc |
|
203.0
|
1.9
|
L
 5.1%
H
1.8
1.9
|
L
 21.6%
H
1.5
1.9
|
L
 45.3%
H
1.3
1.9
|
L
 -40.8%
H
1.1
3.4
|
L
 -1.1%
H
0.9
3.4
|
L
 -77.1%
H
0.9
9.9
|
L
 -87.9%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
55.4
|
9
|
L
 -12.9%
H
9
10.5
|
L
 -1.4%
H
8.3
10.5
|
L
 -18.8%
H
8.3
13.7
|
L
 -11.9%
H
5.8
13.7
|
L
 -76.6%
H
3.8
37.1
|
L
 -72.3%
H
3.8
60.3
|
L
 -98.9%
H
3.8
937.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
4,897.4
|
29.7
|
L
 0.2%
H
29.6
30.5
|
L
 5.0%
H
27.5
30.5
|
L
 4.3%
H
27.5
30.5
|
L
 -5.5%
H
27.5
36.3
|
L
 4.1%
H
25.2
36.5
|
L
 13.5%
H
22.0
36.5
|
L
 45.5%
H
18.0
36.5
|
L
 -58.4%
H
12.0
73.2
|
| Allogene Therapeutics Inc |
|
384.3
|
1.7
|
L
 14.8%
H
1.7
1.9
|
L
 26.7%
H
1.3
1.9
|
L
 20.4%
H
1.3
1.9
|
L
 13.3%
H
1.0
1.9
|
L
 -27.2%
H
0.9
3.8
|
L
 -71.2%
H
0.9
8.4
|
L
 -93.9%
H
0.9
39.1
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
18.8
|
1.2
|
L
 -1.7%
H
1.2
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 2.6%
H
1.0
1.2
|
L
 -33.5%
H
1.0
1.8
|
L
 9.4%
H
0.6
2.1
|
L
 -100.0%
H
0.1
13157.2
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
52,619.6
|
398.3
|
L
 -0.3%
H
392.6
409.6
|
L
 -0.5%
H
383.8
427.1
|
L
 -4.1%
H
383.8
427.1
|
L
 -12.8%
H
383.8
495.6
|
L
 65.6%
H
205.9
495.6
|
L
 81.3%
H
142.0
495.6
|
L
 171.6%
H
117.6
495.6
|
L
 370.7%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
30.8
|
1.2
|
L
 -4.1%
H
1.1
1.2
|
L
 -6.4%
H
1.1
1.3
|
L
 -19.3%
H
1.0
1.6
|
L
 -14.6%
H
1.0
2.2
|
L
 -39.4%
H
1.0
3.5
|
L
 -56.7%
H
1.0
7.4
|
L
 -95.7%
H
1.0
46.6
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
419.5
|
4.0
|
L
 -1.5%
H
4.0
4.2
|
L
 14.5%
H
3.9
4.5
|
L
 -27.2%
H
3.5
6.0
|
L
 0.5%
H
3.5
6.0
|
L
 -46.0%
H
2.9
7.7
|
L
 -71.2%
H
2.1
17.2
|
L
 -71.5%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
| Alvotech |
|
1,445.8
|
4.6
|
L
 -1.9%
H
4.6
4.9
|
L
 -7.2%
H
4.4
5.0
|
L
 -16.6%
H
4.4
5.9
|
L
 -44.1%
H
4.3
9.0
|
L
 -65.0%
H
4.3
13.7
|
L
 -61.2%
H
4.3
18
|
L
H
4.3
18
|
L
H
4.3
18
|
| Kalaris Therapeutics Inc |
|
182.9
|
9.8
|
L
 18.4%
H
8.3
10.2
|
L
 17.8%
H
7.9
10.2
|
L
 37.4%
H
7.1
11.9
|
L
 111.7%
H
4.3
11.9
|
L
 2073.3%
H
0.4
12.9
|
L
 92.9%
H
0.4
12.9
|
L
 -77.2%
H
0.4
48.3
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
9.1
|
2.4
|
L
 2.1%
H
2.3
2.4
|
L
 25.8%
H
1.9
2.4
|
L
 10.1%
H
1.7
2.4
|
L
 2.6%
H
1.7
2.7
|
L
 -76.7%
H
1.7
11.0
|
L
 -99.7%
H
1.7
1071.9
|
L
H
1.7
45292.5
|
L
H
1.7
45292.5
|
| Amgen |
|
175,598.5
|
326.1
|
L
 -1.2%
H
323.9
332.1
|
L
 -0.5%
H
318.2
343.1
|
L
 3.9%
H
312.4
343.1
|
L
 10.4%
H
288
346.4
|
L
 23.4%
H
260.6
346.4
|
L
 20.7%
H
211.7
346.9
|
L
 36.7%
H
198.6
346.9
|
L
 116.4%
H
133.6
346.9
|
| Amylyx Pharma Inc |
|
1,340.9
|
12.2
|
L
 3.2%
H
11.8
12.5
|
L
 6.9%
H
10.8
12.5
|
L
 -7.8%
H
10.8
13.4
|
L
 -15.6%
H
10.8
17.0
|
L
 223.9%
H
2.6
17.0
|
L
 -65.7%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,274.7
|
27.7
|
L
H
27.4
28.0
|
L
 4.8%
H
26.1
28.3
|
L
 8.2%
H
25.2
28.3
|
L
 11.1%
H
22.9
29
|
L
 -24.3%
H
20.4
39.0
|
L
 -1.1%
H
20.4
67.7
|
L
 40.1%
H
16.9
67.7
|
L
 114.5%
H
10.5
67.7
|
| AnaptysBio Inc |
|
1,236.8
|
44.7
|
L
 2.0%
H
42.5
46.3
|
L
 -0.6%
H
42
47.4
|
L
 2.0%
H
42
52.5
|
L
 40.6%
H
30.3
52.5
|
L
 211.1%
H
12.2
52.5
|
L
 103.0%
H
12.2
52.5
|
L
 76.3%
H
12.2
52.5
|
L
H
10
134
|
| Anebulo Pharma Inc |
|
46.8
|
1.1
|
L
 -4.2%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -48.7%
H
0.9
2.4
|
L
 -51.1%
H
0.9
2.9
|
L
 -30.1%
H
0.9
3.4
|
L
 -56.0%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| ANI Pharma Inc |
|
1,713.1
|
76.3
|
L
 -5.9%
H
75.1
81.4
|
L
 -2.7%
H
75.1
81.4
|
L
 -6.6%
H
75.1
84.4
|
L
 -16.0%
H
75.1
97
|
L
 40.8%
H
52.7
99.5
|
L
 80.5%
H
36.5
99.5
|
L
 143.6%
H
22.3
99.5
|
L
 95.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
111.3
|
3.4
|
L
 -1.2%
H
3.3
3.6
|
L
 7.0%
H
3.1
3.6
|
L
 -33.2%
H
3.1
5.2
|
L
 -31.3%
H
3.1
5.5
|
L
 50.2%
H
2.1
5.5
|
L
 -19.3%
H
2.1
6.5
|
L
 -13.6%
H
2.1
8.1
|
L
 14.6%
H
0.6
8.1
|
| Annexon Inc |
|
782.5
|
5.3
|
L
 -0.8%
H
5.2
5.5
|
L
 11.9%
H
4.5
5.7
|
L
 8.0%
H
4.5
5.7
|
L
 61.0%
H
2.5
5.7
|
L
 8.5%
H
1.3
5.7
|
L
 12.4%
H
1.3
8.4
|
L
 -76.5%
H
1.3
38.0
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
35.6
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 17.1%
H
1
1.4
|
L
 13.0%
H
1
1.4
|
L
 4.8%
H
1
1.4
|
L
H
1
1.6
|
L
 -87.4%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
6.8
|
1.6
|
L
 -3.7%
H
1.5
1.7
|
L
 5.4%
H
1.3
1.7
|
L
 -49.2%
H
1.2
3.4
|
L
 -64.8%
H
1.2
6.2
|
L
 -99.0%
H
0.7
157.5
|
L
 -100.0%
H
0.7
28335
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2244000
|
| Apollomics Inc (Class A) |
|
47.1
|
22.0
|
L
 -2.4%
H
21.9
23.0
|
L
 13.8%
H
17.5
23.0
|
L
 22.1%
H
14.8
24.2
|
L
 19.2%
H
10.0
42.1
|
L
 112.5%
H
3.7
42.1
|
L
 -97.9%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
3,454.1
|
27.3
|
L
 4.0%
H
26.2
27.5
|
L
 5.6%
H
23.7
27.5
|
L
 14.8%
H
23.7
27.5
|
L
 6.1%
H
18.8
30.5
|
L
 -17.3%
H
16.1
31.2
|
L
 -42.7%
H
16.1
94.8
|
L
 -52.4%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
14.4
|
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -60%
H
0.1
0.3
|
L
 -90.5%
H
0.1
1.5
|
L
 -86.3%
H
0.1
1.5
|
L
 -89.9%
H
0.1
10.6
|
L
 -99.6%
H
0.1
29.8
|
L
H
0.1
57.4
|
| Aptorum Grp Ltd (Class A) |
|
8.6
|
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 -20.5%
H
1.0
1.4
|
L
 -55.7%
H
1.0
2.4
|
L
 -26.6%
H
0.7
4.5
|
L
 -78.1%
H
0.5
17.5
|
L
 -96.1%
H
0.5
49.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
6.6
|
0.9
|
L
H
0.9
1
|
L
 10.6%
H
0.8
1
|
L
 1.1%
H
0.8
1.0
|
L
 -36.5%
H
0.8
1.7
|
L
 -76.1%
H
0.8
4.7
|
L
 -89.7%
H
0.8
12
|
L
 -99.1%
H
0.8
169.2
|
L
H
0.8
1062.2
|
| Aptevo Therapeutics Inc |
|
9.0
|
9.7
|
L
 5%
H
8.1
9.9
|
L
 2.9%
H
7.7
9.9
|
L
 -56.7%
H
7.7
23.2
|
L
 -69.5%
H
7.7
31.1
|
L
 -99.5%
H
7.7
1868.4
|
L
 -100.0%
H
7.7
1512086.4
|
L
 -100.0%
H
7.7
25324516.8
|
L
H
7.7
68020444.8
|
| AquaBounty Tech Inc |
|
3.5
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 -6.3%
H
0.9
1.0
|
L
 -9.2%
H
0.8
1.1
|
L
 -53.9%
H
0.8
2
|
L
 20.3%
H
0.5
3.0
|
L
 -94.4%
H
0.5
23.6
|
L
 -99.5%
H
0.5
266.4
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
477.0
|
3.9
|
L
 -37.0%
H
3.6
4.2
|
L
 -39.4%
H
3.6
6.5
|
L
 -35.9%
H
3.6
6.6
|
L
 -41.6%
H
3.6
7.6
|
L
 24.9%
H
2.1
7.6
|
L
 320.4%
H
0.7
7.6
|
L
 -26.9%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
192.6
|
6.8
|
L
 0.2%
H
6.7
7.0
|
L
 8.5%
H
6.1
7.0
|
L
 -5.8%
H
6.0
7.8
|
L
 -65.6%
H
5.9
24.2
|
L
 -64.2%
H
5.9
24.2
|
L
 -58.7%
H
5.9
45
|
L
 -90.3%
H
5.9
89.2
|
L
 -82.3%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,880.6
|
7.7
|
L
 10.6%
H
7.2
8.1
|
L
 25.9%
H
5.5
8.1
|
L
 33.5%
H
5.5
8.1
|
L
 53.0%
H
4.7
8.1
|
L
 44.9%
H
3.2
8.1
|
L
 184.6%
H
2.7
10.1
|
L
 10.6%
H
0.5
10.1
|
L
 -27.8%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,456.7
|
28.2
|
L
 -5.6%
H
28.1
30.8
|
L
 -2.7%
H
28.1
30.8
|
L
 -5.2%
H
27.5
30.8
|
L
 36.3%
H
19.6
31.8
|
L
 84.8%
H
11.1
31.8
|
L
 94.9%
H
1.8
31.8
|
L
 0.2%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
2.9
|
1.4
|
L
 -11.3%
H
1.4
1.6
|
L
 11.8%
H
1.3
1.8
|
L
 -23.7%
H
1.2
2.1
|
L
 -70.7%
H
1.2
4.9
|
L
 -79.8%
H
1.2
28.6
|
L
 -93.1%
H
1.2
28.6
|
L
 -98.5%
H
1.2
330.3
|
L
H
1.2
15552
|
| Arvinas Inc |
|
775.2
|
12.1
|
L
 -0.9%
H
12.1
12.4
|
L
 5.2%
H
11
12.7
|
L
 -7.9%
H
11
13.4
|
L
 25.9%
H
8.8
14.2
|
L
 -39.1%
H
5.9
20.4
|
L
 -57.8%
H
5.9
53.1
|
L
 -85.0%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
8,970.8
|
64.6
|
L
 -0.7%
H
63.5
67.0
|
L
 -4.8%
H
60.6
76.8
|
L
 -6.2%
H
59.5
76.8
|
L
 79.0%
H
34.6
76.8
|
L
 226.9%
H
9.6
76.8
|
L
 113.2%
H
9.6
76.8
|
L
 -19.2%
H
9.6
93.7
|
L
 1104.5%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
502.0
|
31.7
|
L
 0.6%
H
31.3
33.7
|
L
 -5.9%
H
29.3
33.7
|
L
 -11.0%
H
29.3
39.0
|
L
 18.3%
H
25.7
39.7
|
L
 87.4%
H
7.8
39.7
|
L
 66.4%
H
7.7
39.7
|
L
 -56.7%
H
7.7
84.2
|
L
 -60.0%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
939.6
|
7.5
|
L
 16.6%
H
7.3
8.1
|
L
 33.4%
H
6.0
8.1
|
L
 19.6%
H
5.2
8.1
|
L
 -15.1%
H
5.2
14.5
|
L
 58.8%
H
3.7
14.5
|
L
 326.7%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
59.0
|
9.2
|
L
 -1.3%
H
9.1
9.5
|
L
 0.6%
H
9.1
9.9
|
L
 -22.3%
H
8.6
12
|
L
 -30.0%
H
8.6
14.3
|
L
 -26.2%
H
7.7
15.2
|
L
 -85.0%
H
7.7
120.2
|
L
 -71.6%
H
7.7
120.2
|
L
 -99.0%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,362.1
|
3.8
|
L
 -5.5%
H
3.7
4.0
|
L
 -3.1%
H
3.6
4.1
|
L
 -14.6%
H
3.6
4.7
|
L
 -31.2%
H
3.6
6.8
|
L
 131.5%
H
1.2
6.8
|
L
 127.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| Athira Pharma Inc |
|
26.6
|
6.8
|
L
 -6.1%
H
6.6
7.4
|
L
 -3.0%
H
6.4
7.5
|
L
 68.3%
H
3.8
8.4
|
L
 72.2%
H
3.6
8.4
|
L
 14.2%
H
2.2
8.4
|
L
 -81.1%
H
2.2
44.1
|
L
 -97.5%
H
2.2
285
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
90.9
|
4.8
|
L
 -2.1%
H
4.7
5.0
|
L
 -6.5%
H
4.7
5.5
|
L
 -57.5%
H
4.7
10.8
|
L
 -78.2%
H
4.7
24.4
|
L
 -68.3%
H
4.7
174.6
|
L
 -99.5%
H
4.7
1016.5
|
L
 -100.0%
H
4.7
49571
|
L
H
4.7
49571
|
| Atossa Therapeutics Inc |
|
82.7
|
0.6
|
L
 -1.5%
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -21.0%
H
0.6
1.0
|
L
 -45.8%
H
0.6
1.2
|
L
 -32.6%
H
0.6
1.3
|
L
 -8.6%
H
0.6
2.3
|
L
 -33.3%
H
0.5
9.8
|
L
 -98.9%
H
0.5
127.8
|
| Atara Biotherapeutics Inc |
|
98.6
|
13.7
|
L
 -21.6%
H
13.1
18.0
|
L
 -23.1%
H
13.1
19.1
|
L
 -12.9%
H
13.1
19.1
|
L
 -15.0%
H
10.5
19.1
|
L
 -17.3%
H
5
19.1
|
L
 -84.4%
H
0.4
141
|
L
 -97.3%
H
0.4
546.3
|
L
 -97.5%
H
0.4
1361.3
|
| Astria Therapeutics Inc |
|
735.3
|
12.9
|
L
 -0.8%
H
12.9
13.3
|
L
 -0.1%
H
12.7
13.3
|
L
 -0.5%
H
12.6
13.3
|
L
 52.4%
H
7.9
13.3
|
L
 54.3%
H
3.6
13.3
|
L
 -14.8%
H
3.6
16.9
|
L
 -9.0%
H
2.4
47.8
|
L
 -97.1%
H
2.4
489
|
| Aurinia Pharma Inc |
|
1,997.4
|
15.2
|
L
 -1.2%
H
15.1
15.6
|
L
 -1.3%
H
14.8
16.2
|
L
 -2.5%
H
14.8
16.5
|
L
 30.4%
H
10.9
16.5
|
L
 82.5%
H
6.6
16.5
|
L
 101.2%
H
4.7
16.5
|
L
 13.1%
H
4.1
34.0
|
L
 526.0%
H
1.4
34.0
|
| Aura Biosciences Inc |
|
323.2
|
5.1
|
L
 -1.4%
H
5
5.4
|
L
 -4.0%
H
5
5.5
|
L
 -19.8%
H
5
6.7
|
L
 -15.6%
H
5
6.7
|
L
 -35.6%
H
4.3
8.3
|
L
 -51.4%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
269.5
|
3.5
|
L
 -4.4%
H
3.4
3.7
|
L
 -0.9%
H
3.3
3.7
|
L
 9.9%
H
3.1
3.7
|
L
 10.2%
H
2.9
3.7
|
L
 3.3%
H
2.5
4.0
|
L
 -26.3%
H
2.5
5.2
|
L
 -92.8%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
384.8
|
20.6
|
L
 -4.2%
H
19
21.8
|
L
 -1.7%
H
19.0
21.9
|
L
 4.4%
H
17.8
22
|
L
 20.4%
H
15.5
26
|
L
 -53.1%
H
13.7
61.1
|
L
 101.6%
H
1.4
61.1
|
L
 -88.6%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
667.2
|
13.5
|
L
 2.1%
H
13.1
13.7
|
L
 -4.5%
H
12.5
14.1
|
L
 0.2%
H
12.5
17.7
|
L
 43.9%
H
8.4
17.7
|
L
 -85.4%
H
6.6
100.1
|
L
 -98.4%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
307.4
|
17.0
|
L
 -0.9%
H
16.8
17.2
|
L
 -0.4%
H
15.2
17.7
|
L
 -11.9%
H
15.2
20.7
|
L
 13.2%
H
13.2
20.7
|
L
 141.1%
H
3.4
20.7
|
L
 243.1%
H
0.0
34.5
|
L
 -43.5%
H
0.0
54
|
L
 -61.8%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
382.4
|
4.3
|
L
 0.2%
H
4.2
4.4
|
L
 16.3%
H
3.6
4.4
|
L
 -3.0%
H
3.5
4.4
|
L
 -55.0%
H
2.9
9.5
|
L
 -62.6%
H
2.9
14.0
|
L
 -56.5%
H
2.9
14.4
|
L
 -24.1%
H
2.9
31.5
|
L
 -7.0%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,538.9
|
169.4
|
L
 1.1%
H
168.5
173.8
|
L
 -5.2%
H
165.8
179.0
|
L
 16.6%
H
144.1
184.4
|
L
 38.3%
H
119.2
184.4
|
L
 105.1%
H
79.2
184.4
|
L
 167.5%
H
53.7
184.4
|
L
 118.0%
H
19.4
184.4
|
L
 1328.2%
H
1.9
184.4
|
| Aytu BioPharma Inc |
|
26.9
|
2.6
|
L
 -0.8%
H
2.6
2.7
|
L
 -4.7%
H
2.6
3.1
|
L
 17.3%
H
2.3
3.1
|
L
 5.2%
H
1.8
3.1
|
L
 48.3%
H
1.0
3.1
|
L
 -26.3%
H
1.0
4.0
|
L
 -98.0%
H
1.0
235.3
|
L
 -100.0%
H
1.0
969600
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.7
|
L
 4.4%
H
0.7
0.8
|
L
 12.5%
H
0.6
0.8
|
L
 2.9%
H
0.5
0.8
|
L
 -18.2%
H
0.5
1
|
L
 -58.1%
H
0.5
2.6
|
L
 -81.1%
H
0.5
5.4
|
L
 -94.9%
H
0.5
18.2
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
72.1
|
1.5
|
L
 -7.3%
H
1.5
1.8
|
L
 -16.9%
H
1.5
1.8
|
L
 -19.9%
H
1.5
2.0
|
L
 -21.5%
H
1.3
2.1
|
L
 -21.5%
H
1.3
3.2
|
L
 -14.0%
H
1.1
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
9.6
|
7.8
|
L
H
7.7
7.8
|
L
 -3.6%
H
7.7
8.4
|
L
 2.9%
H
7.0
8.9
|
L
 -12.6%
H
7.0
12.0
|
L
 -3.6%
H
6.5
12.1
|
L
 -44.3%
H
5
45.6
|
L
 -96.4%
H
5
377.4
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
10.0
|
0.3
|
L
H
0.3
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -20%
H
0.2
0.5
|
L
 -72.6%
H
0.2
1
|
L
 -78.1%
H
0.2
1.7
|
L
 -97.4%
H
0.2
10.8
|
L
 -99.3%
H
0.2
84.2
|
L
 -99.9%
H
0.2
444
|
| Amarin Corp (ADR) |
|
328.9
|
15.8
|
L
 -3.5%
H
15.7
16.8
|
L
 15.3%
H
13.1
16.8
|
L
 12.0%
H
13.1
16.8
|
L
 -17.0%
H
13.1
20.9
|
L
 2776.4%
H
0.4
20.9
|
L
 968.9%
H
0.4
20.9
|
L
 169.5%
H
0.4
20.9
|
L
 870.6%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
48,794.4
|
788.5
|
L
 -0.9%
H
787.4
816.5
|
L
 -6.1%
H
787.0
835.5
|
L
 -11.4%
H
787.0
903.3
|
L
 -2.0%
H
749.8
934.6
|
L
 21.4%
H
510.1
934.6
|
L
 111.4%
H
327.7
934.6
|
L
 172.8%
H
248.2
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
12,402.3
|
203.0
|
L
 -2.8%
H
201.1
214
|
L
 -4.8%
H
201.1
219.3
|
L
 3.2%
H
192.3
229.9
|
L
 -5.5%
H
186.1
229.9
|
L
 51%
H
118.0
229.9
|
L
 85.8%
H
64.3
229.9
|
L
 20.1%
H
61.6
229.9
|
L
 1300.9%
H
11.9
229.9
|
| Alterity Therapeutics Ltd (ADR) |
|
63.8
|
3.5
|
L
 5.7%
H
3.4
3.5
|
L
 11.4%
H
3.1
3.5
|
L
 4.8%
H
2.7
3.5
|
L
 -21.8%
H
2.7
5.2
|
L
 5.4%
H
2.5
7
|
L
 2.0%
H
1
7
|
L
 -76.8%
H
1
27.5
|
L
 -91.2%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
481.7
|
1.8
|
L
 -5.2%
H
1.8
2.0
|
L
 -3.2%
H
1.8
2.1
|
L
 21.5%
H
1.5
2.1
|
L
 2.8%
H
1.2
2.1
|
L
 -24.9%
H
1.1
2.7
|
L
 0.6%
H
1.1
7.5
|
L
 -80.5%
H
1.1
9.4
|
L
H
1.1
53.2
|
| Avadel Pharma PLC (ADR) |
|
2,110.0
|
21.5
|
L
 0.1%
H
21.5
21.5
|
L
 -0.1%
H
21.4
21.5
|
L
 0.9%
H
21.3
21.7
|
L
 51.4%
H
13.8
23.6
|
L
 101.1%
H
6.4
23.6
|
L
 207.6%
H
6.4
23.6
|
L
 214.3%
H
1.1
23.6
|
L
 110.4%
H
1.0
23.6
|
| Astrazeneca PLC (ADR) |
|
293,468.7
|
94.7
|
L
 0.7%
H
94.5
95.9
|
L
 3.4%
H
89.5
96.5
|
L
 5.4%
H
89.3
96.5
|
L
 11.3%
H
80.5
96.5
|
L
 42.2%
H
61.2
96.5
|
L
 33.5%
H
60.5
96.5
|
L
 86.1%
H
46.5
96.5
|
L
 197.9%
H
25.6
96.5
|
| BridgeBio Pharma Inc |
|
14,886.8
|
77.3
|
L
 4.7%
H
74.5
78.4
|
L
 -1.3%
H
71.2
78.6
|
L
 7.8%
H
70.4
78.6
|
L
 41.0%
H
52.8
78.6
|
L
 162.3%
H
28.1
78.6
|
L
 936.9%
H
7.2
78.6
|
L
 17.9%
H
5.0
78.6
|
L
H
5.0
78.6
|
| BioAtla Inc |
|
21.2
|
0.4
|
L
 -10%
H
0.4
0.4
|
L
 -32.1%
H
0.4
0.6
|
L
 -55%
H
0.4
0.9
|
L
 -64.7%
H
0.4
1.4
|
L
 -35.7%
H
0.2
1.4
|
L
 -95.3%
H
0.2
5
|
L
 -99.1%
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
14.9
|
1.4
|
L
 6.1%
H
1.3
1.4
|
L
 10.2%
H
1.3
1.4
|
L
 -3.5%
H
1.2
1.5
|
L
 0.7%
H
1.2
1.6
|
L
 -37.5%
H
1
3.2
|
L
 -95.9%
H
1
43.8
|
L
 -97.5%
H
1
82.2
|
L
 -99.1%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
1,559.5
|
7.4
|
L
 -2.9%
H
7.4
8.0
|
L
 -1.3%
H
7.2
8.1
|
L
 -3.1%
H
7.1
8.1
|
L
 2.1%
H
6
8.2
|
L
 -8.1%
H
6
11.3
|
L
 -30.4%
H
4.0
11.3
|
L
 -4.4%
H
4.0
20.0
|
L
 -12.9%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
13.7
|
7.3
|
L
 -0.4%
H
7
7.7
|
L
 1.1%
H
7.0
8.2
|
L
 -41.0%
H
6.6
12.9
|
L
 -42.6%
H
6.6
14.7
|
L
 -98.9%
H
6.6
982
|
L
 -99.9%
H
6.6
12033
|
L
 -99.9%
H
6.6
18526.5
|
L
 -100.0%
H
6.6
138373.2
|
| Black Diamond Therapeutics Inc |
|
160.1
|
2.8
|
L
 1.1%
H
2.7
2.9
|
L
 12.9%
H
2.5
2.9
|
L
 3.7%
H
2.4
2.9
|
L
 -35.0%
H
2.2
4.9
|
L
 38.4%
H
1.2
4.9
|
L
 27.7%
H
1.2
7.7
|
L
 -91.8%
H
1.2
37.8
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,795.6
|
27.6
|
L
 -1.6%
H
27.3
28.7
|
L
 1.5%
H
26.3
30.5
|
L
 4.0%
H
25.5
30.5
|
L
 -1.2%
H
20.2
31.5
|
L
 2.8%
H
13.5
35.3
|
L
 -28.8%
H
13.5
50.7
|
L
 -72.9%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
9.6
|
0.8
|
L
H
0.8
0.8
|
L
 13.9%
H
0.7
0.9
|
L
 2.5%
H
0.6
0.9
|
L
 -21.2%
H
0.6
1.2
|
L
 -30.5%
H
0.5
1.2
|
L
 -95.9%
H
0.5
21
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
27,524.3
|
187.6
|
L
 0.9%
H
186.5
190.2
|
L
 5.5%
H
171.6
190.2
|
L
 6.7%
H
168.6
190.2
|
L
 25.4%
H
138
190.2
|
L
 23.5%
H
110.0
190.2
|
L
 -31.7%
H
110.0
319.8
|
L
 -25.7%
H
110.0
468.6
|
L
 -27.4%
H
110.0
468.6
|
| BioVie Inc |
|
9.6
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -4.5%
H
1.3
1.4
|
L
 -18.1%
H
1.1
1.6
|
L
 -34.9%
H
1.1
2.1
|
L
 -94.6%
H
1.1
23.0
|
L
 -99.8%
H
1.1
1139
|
L
 -99.9%
H
1.1
4609.8
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
100.4
|
1.4
|
L
 6.0%
H
1.3
1.4
|
L
 6.0%
H
1.2
1.4
|
L
 6.0%
H
1.2
1.6
|
L
 -20.7%
H
0.9
1.8
|
L
 -66.7%
H
0.9
4.6
|
L
 -79.1%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
11,325.1
|
59.0
|
L
 -2.3%
H
58.8
60.8
|
L
 -0.8%
H
58.4
61.9
|
L
 9.7%
H
50.9
63.9
|
L
 9.5%
H
50.8
63.9
|
L
 -13.8%
H
50.8
73.5
|
L
 -45.0%
H
50.8
117.8
|
L
 -34.4%
H
50.8
117.8
|
L
 -38.4%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
16.1
|
1.6
|
L
 -1.3%
H
1.6
1.6
|
L
 -0.6%
H
1.6
1.6
|
L
 -4.8%
H
1.5
1.7
|
L
 -25.8%
H
1.5
2.2
|
L
 587.0%
H
0.1
11.6
|
L
 -89.8%
H
0.1
20.2
|
L
 -96.6%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
400.9
|
11.8
|
L
 -2.8%
H
11.7
12.3
|
L
 -5.9%
H
11.2
12.8
|
L
 -11.1%
H
9.9
14.4
|
L
 -16.6%
H
9.9
16.8
|
L
 7.1%
H
9.7
17.2
|
L
 266.6%
H
1.9
17.2
|
L
 -79.8%
H
1.9
178.3
|
L
 -98.8%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
11.2
|
5.8
|
L
 0.3%
H
5.6
5.9
|
L
 0.7%
H
5.5
6.1
|
L
 -0.7%
H
5
6.2
|
L
 -1.5%
H
4.4
6.4
|
L
 -48.4%
H
4.4
11.7
|
L
 -80.0%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Bon Natural Life Ltd |
|
13.7
|
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -3.4%
H
1.5
1.9
|
L
 -19.5%
H
1.5
2.3
|
L
 -96.0%
H
1.1
73.8
|
L
 -99.5%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
44.0
|
2.0
|
L
 0.5%
H
1.9
2.0
|
L
 18.2%
H
1.7
2.1
|
L
 -5.6%
H
1.5
2.3
|
L
 -27.7%
H
1.5
2.8
|
L
 415.4%
H
0.2
8.1
|
L
 -91.0%
H
0.2
34.1
|
L
 -96.2%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
30.6
|
1.7
|
L
H
1.6
1.8
|
L
 6.8%
H
1.5
1.9
|
L
 -37.9%
H
1.4
3.2
|
L
 -58.3%
H
1.4
4.1
|
L
 2050%
H
0.1
5.9
|
L
 50.9%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
65.4
|
1.6
|
L
H
1.6
1.6
|
L
 -1.2%
H
1.4
1.7
|
L
 -18.0%
H
1.4
2.4
|
L
 -12.2%
H
1.4
2.4
|
L
 -2.5%
H
1.0
3.4
|
L
 -16.3%
H
0.7
4
|
L
 -87.4%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
460.6
|
6.6
|
L
 0.2%
H
6.6
6.8
|
L
 -0.6%
H
6.3
7
|
L
 -6.4%
H
6.3
7.7
|
L
 -25.1%
H
6.0
9.1
|
L
 -53.1%
H
6.0
15.4
|
L
 -78.0%
H
6.0
31.4
|
L
 -66.2%
H
6.0
62.1
|
L
H
6.0
62.1
|
| Biodexa Pharma PLC (ADR) |
|
2.0
|
2.4
|
L
 1.7%
H
2.3
2.5
|
L
 -4.5%
H
2.2
2.6
|
L
 -42.3%
H
2.2
8.9
|
L
 -78.4%
H
2.2
10.4
|
L
 -94.5%
H
2.2
92
|
L
 -100.0%
H
2.2
1900000
|
L
 -100.0%
H
2.2
38295000
|
L
 -100.0%
H
2.2
2780000000
|
| BeiGene Ltd (ADR) |
|
35,994.1
|
337.9
|
L
 5.5%
H
328.7
340.8
|
L
 8.6%
H
312.7
340.8
|
L
 6.0%
H
299.5
340.8
|
L
 0.6%
H
299.5
385.2
|
L
 48.0%
H
228.9
385.2
|
L
 37.4%
H
127.0
385.2
|
L
 21.0%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
12.7
|
2.9
|
L
 -2.0%
H
2.9
3.0
|
L
 4.3%
H
2.8
3.0
|
L
 -10.2%
H
2.7
3.4
|
L
 -30.1%
H
2.7
4.2
|
L
 -48.8%
H
0.1
7.8
|
L
 -89.5%
H
0.1
101.2
|
L
 -97.2%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,940.8
|
158.4
|
L
 -3.4%
H
155.5
166
|
L
 -0.6%
H
153.6
170.2
|
L
 6.2%
H
141.0
170.2
|
L
 101.7%
H
77.6
170.2
|
L
 183.1%
H
49
170.2
|
L
 428.2%
H
11
170.2
|
L
H
6
170.2
|
L
H
6
170.2
|
| Neuphoria Therapeutics Inc |
|
22.5
|
4.2
|
L
 3.0%
H
4.0
4.3
|
L
 9.7%
H
3.8
4.4
|
L
 -8.9%
H
3.6
4.6
|
L
 -78.0%
H
3.6
19.2
|
L
 29.7%
H
3
21.4
|
L
 9.4%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
25,055.4
|
99.9
|
L
 1.0%
H
98.9
100.6
|
L
 3.3%
H
95.9
101.5
|
L
 4.2%
H
91.1
101.5
|
L
 -4.4%
H
91.1
113.4
|
L
 -18.3%
H
81.2
126.8
|
L
 -32.9%
H
76.5
154.2
|
L
 -0.5%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.8
|
L
 -5%
H
0.8
0.8
|
L
 4.1%
H
0.7
0.9
|
L
 -38.7%
H
0.6
1.3
|
L
 -48.7%
H
0.6
1.6
|
L
 -73.9%
H
0.6
6.2
|
L
 -71.7%
H
0.6
6.2
|
L
 -97.7%
H
0.6
99
|
L
 -98.0%
H
0.6
620
|
| Cabaletta Bio Inc |
|
202.2
|
2.1
|
L
 -3.2%
H
2.1
2.2
|
L
 -5.0%
H
2
2.3
|
L
 -16%
H
2
2.5
|
L
 -26.3%
H
2
3.7
|
L
 -9.5%
H
1.0
3.7
|
L
 -77.4%
H
1.0
26.4
|
L
 -84.2%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
84.3
|
5.9
|
L
 9.8%
H
5.1
6.2
|
L
 -13.2%
H
5.1
7.0
|
L
 26.4%
H
4.2
7.2
|
L
 73.1%
H
3.0
7.2
|
L
 95%
H
1.4
7.2
|
L
 -34.7%
H
1
10.6
|
L
 -98.4%
H
1
492.5
|
L
H
1
530.3
|
| Capricor Therapeutics Inc |
|
1,296.9
|
23.8
|
L
 -6.7%
H
23.2
26.2
|
L
 -15.8%
H
23.2
28.5
|
L
 -12.9%
H
23.2
30.7
|
L
 212.9%
H
4.3
40.4
|
L
 72.0%
H
4.3
40.4
|
L
 530.7%
H
2.7
40.4
|
L
 448.0%
H
2.6
40.4
|
L
 -1.5%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
42.7
|
4.6
|
L
 7.6%
H
4.0
4.7
|
L
 11.5%
H
3.9
4.7
|
L
 6.1%
H
3.8
4.7
|
L
 -89.4%
H
3.7
43.7
|
L
 -68.1%
H
3.7
43.7
|
L
 -98.7%
H
3.7
449.6
|
L
 -99.2%
H
3.7
1067.3
|
L
 -99.2%
H
3.7
1067.3
|
| CASI Pharma Inc |
|
22.6
|
1.1
|
L
 3.8%
H
1.0
1.2
|
L
 34.2%
H
0.8
1.2
|
L
 27.9%
H
0.8
1.2
|
L
 -46.3%
H
0.8
2.1
|
L
 -61.5%
H
0.8
3.1
|
L
 -42.4%
H
0.8
8.5
|
L
 -96.2%
H
0.8
39
|
L
 -87.8%
H
0.8
88.9
|
| Crescent Biopharma Inc |
|
-
|
10.8
|
L
 -1.6%
H
10.6
11.2
|
L
 -2.6%
H
10.6
11.7
|
L
 -22.8%
H
10.6
15.6
|
L
 -12.1%
H
9.8
16.4
|
L
 -4.9%
H
7.6
21.4
|
L
 84.4%
H
2.8
21.4
|
L
 -28.0%
H
0.9
21.4
|
L
 -89.9%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
207.4
|
2.1
|
L
 -2.3%
H
2.1
2.3
|
L
 10.9%
H
2.0
2.3
|
L
 -17.4%
H
1.9
2.7
|
L
 -11.2%
H
1.9
2.8
|
L
 -44.3%
H
1.1
4.1
|
L
 -70.1%
H
1.1
11.9
|
L
 -93.7%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
520.3
|
6.5
|
L
 -0.6%
H
6.5
6.7
|
L
 4.3%
H
6.3
6.9
|
L
 0.2%
H
6.2
7.1
|
L
 -13.8%
H
6.2
8.0
|
L
 21.9%
H
5.2
14.7
|
L
 241.4%
H
1.3
14.7
|
L
 35.0%
H
1.2
23.7
|
L
 55.2%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
643.9
|
10.9
|
L
 -2.2%
H
10.7
11.6
|
L
 7.7%
H
9.4
11.6
|
L
 -11.8%
H
9.4
13.1
|
L
 54.6%
H
6.7
13.3
|
L
 -2.1%
H
5.7
13.3
|
L
 3.9%
H
5.7
30.2
|
L
 -63.6%
H
5.7
59.9
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
175.8
|
1.9
|
L
 14.6%
H
1.7
1.9
|
L
 21.3%
H
1.5
1.9
|
L
 13.9%
H
1.4
1.9
|
L
 -2.1%
H
1.4
2.4
|
L
 18.2%
H
1.1
2.7
|
L
 108.9%
H
0.5
3.0
|
L
 -85.9%
H
0.5
14.2
|
L
 -68.5%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
124.5
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -4.1%
H
1.3
1.6
|
L
 -16.1%
H
1.3
1.8
|
L
 -27.7%
H
1.3
2.1
|
L
 78.5%
H
0.2
3.8
|
L
 -36.8%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
204.3
|
1.7
|
L
 10.5%
H
1.5
1.8
|
L
 23.4%
H
1.4
1.8
|
L
 31.0%
H
1.3
1.8
|
L
 -7.1%
H
1.1
1.9
|
L
 11.9%
H
0.7
1.9
|
L
 -81.2%
H
0.7
11.0
|
L
 -90.7%
H
0.7
22.2
|
L
 -90.7%
H
0.7
32.0
|
| Cingulate Inc |
|
33.3
|
4.6
|
L
 -8.9%
H
4.6
5.1
|
L
 5.7%
H
4.3
5.5
|
L
 18.4%
H
3.8
5.5
|
L
 6.4%
H
3.2
5.5
|
L
 7.4%
H
3.2
6.0
|
L
 387.4%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
66.1
|
6.4
|
L
 7.2%
H
5.9
6.7
|
L
 10.9%
H
5.7
6.7
|
L
 2.7%
H
5.5
7.0
|
L
 -32.2%
H
5.4
13.5
|
L
 21.2%
H
2.3
13.5
|
L
 -69.2%
H
2.3
39.8
|
L
 -95.4%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.1
|
3.1
|
L
 -7.0%
H
3.1
3.4
|
L
 -11.2%
H
3.1
3.7
|
L
 -21.4%
H
2.5
4.1
|
L
 -35.4%
H
2.5
5.1
|
L
 -67.0%
H
2.5
20.6
|
L
 -94.3%
H
2.5
133.5
|
L
 -99.5%
H
2.5
894
|
L
 -100.0%
H
2.5
22200
|
| Clearmind Medicine Inc |
|
3.5
|
2.4
|
L
 -3.3%
H
2.3
2.5
|
L
 18.1%
H
2.1
2.7
|
L
 -51.8%
H
1.7
4.8
|
L
 -93.9%
H
1.7
48
|
L
 -95.9%
H
1.7
64.8
|
L
 -99.9%
H
1.7
6120
|
L
 -100.0%
H
1.7
788400
|
L
H
1.7
788400
|
| Compass Therapeutics Inc |
|
951.6
|
5.4
|
L
 3.5%
H
5.2
5.7
|
L
 3.5%
H
4.8
5.7
|
L
 4.1%
H
4.8
5.7
|
L
 31.5%
H
3.5
5.9
|
L
 187.6%
H
1.3
5.9
|
L
 3.9%
H
0.8
5.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
3.6
|
5.8
|
L
 -2.0%
H
5.8
6.4
|
L
 9.8%
H
5.2
6.4
|
L
 -16.7%
H
5.2
8.1
|
L
 -42.1%
H
5.2
10.3
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
6600000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
147.9
|
1.6
|
L
 0.6%
H
1.6
1.7
|
L
 3.9%
H
1.5
2
|
L
 54.8%
H
1
2
|
L
 15%
H
1
2
|
L
 33.1%
H
0.5
2
|
L
 91.7%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
15.7
|
1.1
|
L
 3.6%
H
1.1
1.2
|
L
 15.2%
H
1.0
1.2
|
L
 7.6%
H
0.9
1.2
|
L
 -6.6%
H
0.9
1.3
|
L
 -52.7%
H
0.9
2.7
|
L
 -47.9%
H
0.9
3.3
|
L
 -93.4%
H
0.9
41.5
|
L
 -99.5%
H
0.9
309.6
|
| Co-Diagnostics Inc |
|
13.0
|
6.2
|
L
 1.1%
H
6.0
6.3
|
L
 11.3%
H
5.3
6.4
|
L
 -43.2%
H
4.8
11.1
|
L
 -52.0%
H
4.8
46.5
|
L
 -73.4%
H
4.8
46.5
|
L
 -92.1%
H
4.8
99.9
|
L
 -98.1%
H
4.8
620.6
|
L
H
4.8
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
76.4
|
14.3
|
L
 -2.7%
H
14.1
15.0
|
L
 -2.3%
H
14.1
16.0
|
L
 -8.4%
H
13.6
16.6
|
L
 -11.5%
H
13
21.4
|
L
 104.6%
H
6.2
21.4
|
L
 -60.9%
H
2.3
43.8
|
L
 39.8%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,426.4
|
35.4
|
L
 -0.6%
H
35.3
36.9
|
L
 1.8%
H
32.9
37
|
L
 -8.3%
H
32.9
42.3
|
L
 118.3%
H
13.8
43.7
|
L
 335.9%
H
3.7
43.7
|
L
 190.0%
H
3.7
43.7
|
L
 196.8%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,439.6
|
45.5
|
L
 -6.6%
H
45.0
49.0
|
L
 0.0%
H
44.5
49.2
|
L
 -3.2%
H
44.5
50.8
|
L
 37.1%
H
31.3
50.8
|
L
 36.6%
H
23.2
50.8
|
L
 63.2%
H
20.8
50.8
|
L
 110.0%
H
14.0
50.8
|
L
 130.9%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
3,944.6
|
37.5
|
L
 2.7%
H
36.2
37.7
|
L
 -1.8%
H
34.3
38.2
|
L
 -54.9%
H
33.0
89
|
L
 -57.6%
H
33.0
89
|
L
 -27.1%
H
33.0
117.3
|
L
 82.7%
H
17.9
117.3
|
L
 38.0%
H
15.8
117.3
|
L
 892.1%
H
3.2
117.3
|
| Cosmos Health Inc |
|
20.5
|
0.6
|
L
 5.8%
H
0.5
0.6
|
L
 5.8%
H
0.5
0.6
|
L
 22.2%
H
0.4
0.6
|
L
 -50%
H
0.4
1.3
|
L
 -14.1%
H
0.3
1.3
|
L
 -87.5%
H
0.3
7.4
|
L
 -99.5%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
74.0
|
5.0
|
L
 2.5%
H
4.5
5.0
|
L
 24.4%
H
3.8
5.4
|
L
 119.0%
H
2.3
5.4
|
L
 39.4%
H
1.9
5.4
|
L
 122.0%
H
1.9
7.3
|
L
 97.2%
H
1.0
7.3
|
L
 60.2%
H
1.0
7.5
|
L
 2.7%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,792.6
|
22.7
|
L
 0.5%
H
22.6
23.2
|
L
 -1.9%
H
22.2
23.4
|
L
 0.8%
H
22.2
25.1
|
L
 9.1%
H
19.9
25.1
|
L
 17.7%
H
19.1
26.6
|
L
 19.5%
H
11.1
26.6
|
L
 552.9%
H
3.3
26.6
|
L
 1095.8%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
145.9
|
8.3
|
L
 -0.6%
H
8.3
8.6
|
L
 5.6%
H
7.6
8.6
|
L
 -17.7%
H
7.6
11.6
|
L
 -47.1%
H
7.6
20.6
|
L
 -33.2%
H
4.6
20.6
|
L
 100.7%
H
2.1
61.9
|
L
 -80.4%
H
2.1
120
|
L
 -80.8%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
155.2
|
1.7
|
L
 -1.8%
H
1.6
1.7
|
L
 4.4%
H
1.5
1.8
|
L
 -11.2%
H
1.5
1.9
|
L
 -39.6%
H
1.5
3.5
|
L
 -3.5%
H
0.7
3.5
|
L
 -75.9%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
100.0
|
1
|
L
H
1.0
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 -7.4%
H
0.9
1.1
|
L
 -8.3%
H
0.9
1.4
|
L
 -25.4%
H
0.8
1.6
|
L
 69.5%
H
0.5
3.1
|
L
 -62.8%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
10.7
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -15.3%
H
0.8
1.0
|
L
 -37.6%
H
0.8
1.4
|
L
 -48.5%
H
0.8
1.7
|
L
 -76.2%
H
0.8
3.7
|
L
 -93.5%
H
0.8
20
|
L
 -99.6%
H
0.8
348
|
L
 -99.6%
H
0.8
372
|
| CorMedix Inc |
|
601.2
|
7.6
|
L
 1.6%
H
7.6
8.2
|
L
 -37.3%
H
7.2
12.3
|
L
 -34.3%
H
7.2
13.0
|
L
 -30.6%
H
7.2
13.0
|
L
 -29.4%
H
5.6
17.4
|
L
 71.8%
H
2.6
17.4
|
L
 -13.1%
H
2.6
18.8
|
L
 -7.5%
H
0.9
22.7
|
| Crinetics Pharma Inc |
|
5,458.8
|
53.3
|
L
 0.0%
H
53.2
56.1
|
L
 14.0%
H
43.4
58.0
|
L
 11.2%
H
43.0
58.0
|
L
 16.4%
H
38.8
58.0
|
L
 9.8%
H
24.1
58.0
|
L
 218.5%
H
15.2
62.5
|
L
 251.0%
H
13.8
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
1,026.2
|
2.7
|
L
 1.1%
H
2.7
2.8
|
L
 -0.7%
H
2.6
2.8
|
L
 -0.4%
H
2.6
3.4
|
L
 -1.1%
H
2.3
3.4
|
L
 32.0%
H
1.6
3.4
|
L
 7.2%
H
1.6
3.4
|
L
 -70.4%
H
1.6
15.8
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,131.0
|
53.8
|
L
 -4.5%
H
53.7
57.4
|
L
 0.1%
H
53.7
60.7
|
L
 -5.6%
H
52.1
60.7
|
L
 -28.1%
H
48.0
78
|
L
 30.4%
H
30.0
78.5
|
L
 15.3%
H
30.0
91.1
|
L
 -72.2%
H
30.0
220.2
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
507.1
|
6.8
|
L
 -1.9%
H
6.7
7
|
L
 -7.2%
H
6.4
7.4
|
L
 -21.7%
H
6.4
8.7
|
L
 -6.3%
H
6.4
9.6
|
L
 20.2%
H
2.5
9.6
|
L
 698.8%
H
0.6
10
|
L
 73.7%
H
0.6
10
|
L
H
0.6
22.1
|
| Champions Oncology Inc |
|
94.1
|
6.8
|
L
 -0.2%
H
6.6
6.9
|
L
 1.8%
H
6.6
6.9
|
L
 8.1%
H
6.1
8.3
|
L
 3.4%
H
6.0
8.3
|
L
 -28.4%
H
5.6
12.0
|
L
 55.5%
H
3.6
12.0
|
L
 -38.0%
H
3.6
14.7
|
L
 78.4%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
737.0
|
4.4
|
L
 2.1%
H
4.2
4.4
|
L
 2.4%
H
4.0
4.5
|
L
 11.8%
H
3.8
4.7
|
L
 26.1%
H
3.1
4.7
|
L
 343.9%
H
0.4
4.7
|
L
 51.0%
H
0.4
5.9
|
L
 -41.2%
H
0.4
10.1
|
L
 -69.4%
H
0.4
35
|
| Cue Biopharma Inc |
|
32.8
|
0.4
|
L
 -7.7%
H
0.3
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -28%
H
0.2
0.5
|
L
 -61.3%
H
0.2
1.0
|
L
 -75.2%
H
0.2
1.5
|
L
 -87.9%
H
0.2
5.1
|
L
 -97.2%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
19.1
|
8.2
|
L
 3.7%
H
7.8
8.4
|
L
 11.5%
H
6.6
8.4
|
L
 -18.1%
H
6.4
12.5
|
L
 -42.4%
H
6.4
14.5
|
L
 -50.6%
H
6.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
6.7
|
1.4
|
L
 0.7%
H
1.4
1.4
|
L
 -2.8%
H
1.3
1.5
|
L
 -16.0%
H
1.3
1.7
|
L
 -73.5%
H
1.2
6.7
|
L
 -98.6%
H
1.2
107.5
|
L
 -99.9%
H
1.2
4212
|
L
 -100.0%
H
1.2
41112
|
L
 -100.0%
H
1.2
784800
|
| Cyclerion Therapeutics Inc |
|
6.3
|
1.7
|
L
 -14.5%
H
1.7
2
|
L
 23.1%
H
1.3
2.3
|
L
 -0.6%
H
1.2
2.3
|
L
 -33.2%
H
1.2
2.5
|
L
 -49.1%
H
1.2
6.3
|
L
 -86.1%
H
1.2
19.1
|
L
 -97.5%
H
1.2
138
|
L
H
1.2
457
|
| Cytokinetics Inc |
|
7,642.8
|
62.5
|
L
 -1.3%
H
62.3
65.0
|
L
 1.3%
H
58.9
66.6
|
L
 1.5%
H
58.9
71.0
|
L
 3.7%
H
54.3
71.0
|
L
 32.0%
H
29.3
71.0
|
L
 47.8%
H
26.0
110
|
L
 190.1%
H
17.7
110
|
L
 560.1%
H
5.8
110
|
| Cellectis (ADR) |
|
442.4
|
4.4
|
L
 -1.6%
H
4.4
4.6
|
L
 -8.1%
H
4.4
4.9
|
L
 -3.9%
H
3.9
5.5
|
L
 5.8%
H
3.1
5.5
|
L
 128.5%
H
1.1
5.5
|
L
 31.3%
H
1.0
5.5
|
L
 -85.1%
H
1.0
34.7
|
L
 -83.4%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.0
|
1.8
|
L
 -0.6%
H
1.8
1.9
|
L
H
1.8
2.0
|
L
 -31.2%
H
1.6
2.7
|
L
 -46.9%
H
1.6
3.5
|
L
 -79.8%
H
1.6
8.8
|
L
 -80.0%
H
1.6
10.8
|
L
 -98.6%
H
1.6
675.2
|
L
H
1.6
736
|
| Compass Pathways PLC (ADR) |
|
693.2
|
7.2
|
L
 -5.3%
H
7.1
7.8
|
L
 10.2%
H
6.3
8.2
|
L
 13.5%
H
6.1
8.2
|
L
 12.1%
H
4.9
8.2
|
L
 74.4%
H
2.3
8.2
|
L
 -5.2%
H
2.3
12.8
|
L
 -84.0%
H
2.3
58.6
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
3,314.1
|
22.4
|
L
 1.7%
H
22.2
23
|
L
 -5.4%
H
21.9
23.7
|
L
 -21.6%
H
21.9
30.0
|
L
 -1.8%
H
17.1
30.6
|
L
 39.3%
H
9.6
30.6
|
L
 602.8%
H
3
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
119.8
|
2.2
|
L
 -3.6%
H
2.1
2.3
|
L
 -14.7%
H
2.1
2.5
|
L
 -9.7%
H
2.0
2.9
|
L
 8.6%
H
1.5
3.3
|
L
 92.0%
H
0.5
3.3
|
L
 156.0%
H
0.5
3.3
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
28.3
|
2.0
|
L
 -4.4%
H
2.0
2.1
|
L
 1.5%
H
1.9
2.1
|
L
 6.5%
H
1.9
2.5
|
L
 -11.2%
H
1.6
2.5
|
L
 -39.1%
H
1.6
9.2
|
L
 -85%
H
0.3
16.8
|
L
 -88.0%
H
0.3
46.2
|
L
 -99.4%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
917.9
|
8.9
|
L
 -3.4%
H
8.9
9.6
|
L
 1.0%
H
8.4
9.7
|
L
 8.4%
H
8.1
10.5
|
L
 20.2%
H
6.9
10.9
|
L
 -26.7%
H
5.6
13.5
|
L
 -59.2%
H
5.6
24
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
197.3
|
7.3
|
L
 -0.6%
H
7.2
7.3
|
L
 -2.4%
H
7.0
7.7
|
L
 -10.6%
H
7.0
8.2
|
L
 -3.7%
H
6.9
9.4
|
L
 81.8%
H
3.5
9.4
|
L
 354.4%
H
1.0
9.4
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
7.7
|
L
 -1.7%
H
7.5
8.2
|
L
 -0.6%
H
7.4
8.2
|
L
 -10.3%
H
7.3
8.9
|
L
 -9.4%
H
6.6
10
|
L
 -11.9%
H
5.5
13.1
|
L
 -7.9%
H
4.1
14.4
|
L
 -89.4%
H
4.1
138.8
|
L
 -99.9%
H
4.1
19125
|
| DiaMedica Therapeutics Inc |
|
425.0
|
8.2
|
L
 -2.3%
H
8.1
8.6
|
L
 2.9%
H
8.0
8.8
|
L
 -10.0%
H
7.7
10.4
|
L
 16.2%
H
5.3
10.4
|
L
 49.5%
H
3.2
10.4
|
L
 403.7%
H
1.3
10.4
|
L
 -14.1%
H
1.1
10.9
|
L
 329.5%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
2,667.2
|
17.1
|
L
 0.1%
H
17.0
17.7
|
L
 5.0%
H
15.3
18.0
|
L
 -13.1%
H
15.3
19.6
|
L
 5.6%
H
13.8
20.6
|
L
 -19.6%
H
10.6
24.3
|
L
 -38.6%
H
10.6
33.3
|
L
 -78.7%
H
10.6
84.0
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
68.4
|
4.3
|
L
 -4.3%
H
4.2
4.5
|
L
 -6.8%
H
4.2
4.9
|
L
 8.1%
H
4.0
5.1
|
L
 -33.0%
H
3.7
6.4
|
L
 261.9%
H
1
13.6
|
L
 18.9%
H
0.8
13.6
|
L
 -77.2%
H
0.8
43.4
|
L
 -97.2%
H
0.8
308.4
|
| DarioHealth Corp |
|
82.2
|
12.2
|
L
 -5.7%
H
12.0
12.7
|
L
 15.6%
H
10.7
13.6
|
L
H
10.0
13.6
|
L
 -22.5%
H
9.0
16.5
|
L
 -32.4%
H
5.9
27.6
|
L
 -87.3%
H
5.9
135.6
|
L
 -96.3%
H
5.9
637
|
L
 -99.6%
H
5.9
3492
|
| Dermata Therapeutics Inc |
|
6.7
|
2.1
|
L
 -2.8%
H
2.1
2.2
|
L
 -4.6%
H
2.1
2.4
|
L
 -28.3%
H
1.6
3.0
|
L
 -54.2%
H
1.6
4.5
|
L
 65.1%
H
0.6
7.1
|
L
 -60.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
675.5
|
86.8
|
L
 -3.6%
H
85.6
92.7
|
L
 3.9%
H
72.0
123.8
|
L
 12.1%
H
72.0
123.8
|
L
 41.3%
H
50
123.8
|
L
 111.4%
H
23.2
123.8
|
L
 2079.6%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
534.9
|
9.4
|
L
 2.3%
H
9.3
9.9
|
L
 3.2%
H
8.2
10.2
|
L
 1.3%
H
8.2
10.2
|
L
 31.9%
H
5.3
10.3
|
L
 84.8%
H
2.6
10.3
|
L
 3.9%
H
1.9
10.3
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
94.4
|
3.9
|
L
 -2.7%
H
3.9
4.1
|
L
 -4.4%
H
3.9
4.6
|
L
 -19.3%
H
3.9
5.2
|
L
 -33.3%
H
3.9
8.8
|
L
 -12.9%
H
3.9
8.8
|
L
 213.6%
H
0.3
19.4
|
L
 -58.9%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Tech Corp |
|
1,751.9
|
15.4
|
L
H
15.4
15.4
|
L
 0.2%
H
15.4
15.5
|
L
 41.5%
H
10.6
15.5
|
L
 48.9%
H
9.7
15.5
|
L
 22.1%
H
9.2
15.5
|
L
 50.0%
H
9.2
15.5
|
L
 208.8%
H
4.8
21.4
|
L
 -42.5%
H
1.8
27.9
|
| Dyne Therapeutics Inc |
|
2,925.9
|
17.8
|
L
 -2.7%
H
17.7
18.7
|
L
 -4.0%
H
17.6
19.9
|
L
 -3.6%
H
17.6
21
|
L
 21.1%
H
13.7
25
|
L
 -22.9%
H
6.4
25
|
L
 55.2%
H
6.4
47.5
|
L
 -34.5%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
789.7
|
17.0
|
L
 0.1%
H
16.9
18.0
|
L
 -10.7%
H
16.5
19.0
|
L
 -0.9%
H
16.5
26.2
|
L
 7.2%
H
12.6
26.2
|
L
 344.1%
H
3.8
26.2
|
L
 9.0%
H
0.5
26.2
|
L
 -56.5%
H
0.5
73.8
|
L
 -94.9%
H
0.5
505.7
|
| Editas Medicine Inc |
|
202.1
|
2.1
|
L
 -3.3%
H
2.1
2.2
|
L
 1.0%
H
2.0
2.2
|
L
 -15.2%
H
2.0
2.7
|
L
 -49.3%
H
2.0
4.3
|
L
 54.5%
H
0.9
4.5
|
L
 -74.8%
H
0.9
11.9
|
L
 -97.7%
H
0.9
88
|
L
H
0.9
100.0
|
| Edesa Biotech Inc |
|
12.5
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
H
1.4
1.6
|
L
 -16.2%
H
1.3
1.8
|
L
 -42.3%
H
1.3
3.0
|
L
 -15.7%
H
1.3
4.5
|
L
 -91.9%
H
1.3
19.7
|
L
 -95.6%
H
1.3
84
|
L
 -99.9%
H
1.3
2037.4
|
| Eledon Pharma Inc |
|
129.8
|
1.7
|
L
H
1.7
1.8
|
L
 6.8%
H
1.6
1.8
|
L
 10.9%
H
1.4
1.8
|
L
 -42.0%
H
1.4
4.6
|
L
 -59.8%
H
1.4
5.0
|
L
 -38.7%
H
1.1
5.4
|
L
 -88.2%
H
1.1
22.9
|
L
 -99.8%
H
1.1
1425.6
|
| Elicio Therapeutics Inc |
|
139.1
|
8.1
|
L
 -2.2%
H
8.0
8.6
|
L
 0.1%
H
7.8
8.6
|
L
 -0.4%
H
7.7
8.8
|
L
 -27.1%
H
7.4
11.2
|
L
 42.2%
H
4.6
12.6
|
L
 -16.0%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,543.0
|
26
|
L
 11.8%
H
23.3
30.0
|
L
 67.3%
H
14.8
30.0
|
L
 33.4%
H
14.8
30.0
|
L
 22.1%
H
14.8
30.0
|
L
 7.7%
H
13.3
30.0
|
L
 37.1%
H
9.8
30.0
|
L
 -51.5%
H
3.9
59.9
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
240.2
|
5.0
|
L
 9.8%
H
4.6
5.2
|
L
 34.1%
H
3.5
5.2
|
L
 164.7%
H
1.9
5.2
|
L
 166.1%
H
1.6
5.2
|
L
 155.3%
H
1.1
5.2
|
L
 22.1%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
213.6
|
0.9
|
L
 7.1%
H
0.8
0.9
|
L
 18.4%
H
0.8
0.9
|
L
 -11.8%
H
0.7
1.1
|
L
 -23.7%
H
0.7
1.8
|
L
 -23.7%
H
0.7
2.1
|
L
 -78.7%
H
0.7
4.7
|
L
 -90.7%
H
0.7
29.4
|
L
 -99.4%
H
0.7
318
|
| Enochian Biosciences Inc |
|
-
|
1.0
|
L
 5.5%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -23.8%
H
0.9
1.3
|
L
 -32.4%
H
0.8
1.7
|
L
 200%
H
0.1
1.7
|
L
 -17.9%
H
0.1
2.3
|
L
 -69.8%
H
0.1
13.8
|
L
 -75.4%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.7
|
1.0
|
L
 -3.8%
H
1
1.1
|
L
 8.5%
H
1.0
1.1
|
L
 -28.2%
H
0.9
1.6
|
L
 -56.2%
H
0.9
2.8
|
L
 -87.1%
H
0.9
9.0
|
L
 -88.7%
H
0.1
18.4
|
L
 -100.0%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
378.4
|
13.1
|
L
 -2.5%
H
13.0
13.6
|
L
 -9.1%
H
13.0
14.8
|
L
 -10.5%
H
13.0
17.2
|
L
 14.4%
H
10.2
17.2
|
L
 146.9%
H
4.1
17.2
|
L
 -72.2%
H
4.1
62.1
|
L
 -71.3%
H
4.1
102
|
L
 -55.7%
H
4.1
127.8
|
| Entera Bio Ltd |
|
73.4
|
1.6
|
L
 -8.1%
H
1.6
1.8
|
L
 -9.6%
H
1.6
1.8
|
L
 -22.7%
H
1.5
2.3
|
L
 -36.3%
H
1.5
3.2
|
L
 -34.7%
H
1.5
3.2
|
L
 68.4%
H
0.5
3.4
|
L
 33.3%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
4.1
|
4.0
|
L
 -2.9%
H
4.0
4.2
|
L
 7.9%
H
3.7
4.3
|
L
 -33.1%
H
3.5
13.3
|
L
 -53.2%
H
3.5
13.3
|
L
 -94.7%
H
3.5
75.6
|
L
 -99.2%
H
3.5
1256.4
|
L
 -100.0%
H
3.5
63000
|
L
 -100.0%
H
3.5
12150000
|
| Evolus Inc |
|
366.2
|
5.7
|
L
 -1.6%
H
5.1
5.8
|
L
 -15.9%
H
5.1
6.7
|
L
 -19.1%
H
5.1
7.3
|
L
 -9.3%
H
5.1
7.8
|
L
 -44.7%
H
5.1
17.1
|
L
 -28.9%
H
5.1
17.8
|
L
 33.3%
H
4.3
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
69.4
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -25.5%
H
1.1
1.6
|
L
 26.7%
H
0.9
1.7
|
L
 -20.8%
H
0.8
1.7
|
L
 58.3%
H
0.3
2.4
|
L
H
0.3
3.3
|
L
 -78.4%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Erasca Inc |
|
1,917.9
|
6.8
|
L
 16.4%
H
5.7
6.9
|
L
 88.3%
H
3.4
6.9
|
L
 104.9%
H
3.2
6.9
|
L
 175.9%
H
2.1
6.9
|
L
 145.8%
H
1.0
6.9
|
L
 76.5%
H
1.0
6.9
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
919.8
|
3.9
|
L
 -0.8%
H
3.8
4.0
|
L
 4.6%
H
3.6
4.2
|
L
 2.4%
H
3.6
4.2
|
L
 57.7%
H
2.4
4.2
|
L
 78.8%
H
0.7
4.2
|
L
 -44.5%
H
0.7
7.4
|
L
 -87.5%
H
0.7
39.5
|
L
 -78.5%
H
0.7
82.7
|
| Eton Pharma Inc |
|
414.6
|
15.5
|
L
 -6.4%
H
15.3
16.5
|
L
 -4.9%
H
15.3
17
|
L
 -5.5%
H
15.3
17.3
|
L
 -23.8%
H
15.3
20.4
|
L
 28.7%
H
11.1
23
|
L
 408.6%
H
2.4
23
|
L
 84.7%
H
2.0
23
|
L
H
2.0
23
|
| Edgewise Therapeutics Inc |
|
2,636.1
|
24.9
|
L
 -0.3%
H
24.6
25.4
|
L
 4.8%
H
22.8
25.4
|
L
 6.7%
H
19.8
27.4
|
L
 55.1%
H
14.3
27.4
|
L
 -2.1%
H
10.6
30.5
|
L
 171.5%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
11,807.7
|
44.0
|
L
 -0.3%
H
43.9
45.4
|
L
 1.1%
H
41.9
46.3
|
L
 5.2%
H
40.7
47.2
|
L
 14.2%
H
33.8
47.2
|
L
 27.7%
H
31.9
49.6
|
L
 161.4%
H
16.2
49.6
|
L
 93.0%
H
14.9
49.6
|
L
 798.8%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
27.0
|
3.3
|
L
 -4.4%
H
3.3
3.6
|
L
 -7.8%
H
3.3
4.1
|
L
 -12.2%
H
2.9
4.4
|
L
 -60.7%
H
2.9
9.5
|
L
 -65.6%
H
0.0
17.2
|
L
 -97.8%
H
0.0
468
|
L
 -99.4%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,343.6
|
16.2
|
L
 -5.0%
H
16.2
17.4
|
L
 -7.2%
H
16.2
18.2
|
L
 -5.0%
H
15.8
19
|
L
 16.1%
H
9.7
19.1
|
L
 78.2%
H
3.9
19.1
|
L
 396.3%
H
2.2
31.0
|
L
 56.8%
H
2.2
31.0
|
L
 -59.0%
H
2.2
42.7
|
| Evaxion Biotech A/S (ADR) |
|
42.4
|
5.1
|
L
 -0.6%
H
5.0
5.3
|
L
 7.9%
H
4.6
5.5
|
L
 -23.4%
H
4.6
6.7
|
L
 -21%
H
4.6
12.2
|
L
 470.8%
H
0.8
12.2
|
L
 -68.8%
H
0.8
21.1
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
1,300.1
|
3.7
|
L
 -0.5%
H
3.6
3.7
|
L
 15.1%
H
3.1
3.7
|
L
 26.2%
H
2.9
3.7
|
L
 -7.1%
H
2.9
4.3
|
L
 -15.1%
H
2.8
4.8
|
L
 -57.4%
H
2.8
13.5
|
L
 -79.8%
H
2.8
26.6
|
L
 74.3%
H
1.6
26.6
|
| Fate Therapeutics Inc |
|
121.1
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 6.1%
H
1.0
1.1
|
L
H
1.0
1.2
|
L
 -34.8%
H
1.0
1.9
|
L
 -37.9%
H
0.7
1.9
|
L
 -80.1%
H
0.7
8.8
|
L
 -99.1%
H
0.7
121.2
|
L
 -63.8%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
133.5
|
4.3
|
L
 -1.8%
H
4.3
4.5
|
L
 6.7%
H
4.0
4.5
|
L
 51.4%
H
2.8
4.5
|
L
 53.6%
H
2.4
4.5
|
L
 106.7%
H
1.3
4.5
|
L
 -64.2%
H
1.2
17.4
|
L
 -91.5%
H
1.2
91.5
|
L
 -89.8%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
299.1
|
23.9
|
L
 -1.2%
H
23.1
26
|
L
 1.1%
H
21.9
27.5
|
L
 18.9%
H
19.8
31.3
|
L
 57.7%
H
10.3
31.3
|
L
 22.8%
H
4.9
31.3
|
L
 -4.5%
H
4.1
32.3
|
L
 -97.3%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
428.5
|
7.5
|
L
 2.7%
H
7.3
7.6
|
L
 2.5%
H
7.0
8.1
|
L
 -28.6%
H
7.0
11.8
|
L
 -21.6%
H
7.0
12.3
|
L
 28.4%
H
2.2
12.3
|
L
 -64.0%
H
2.2
36.3
|
L
 -83.0%
H
2.2
55.1
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
265.4
|
7.8
|
L
 2.5%
H
7.7
8.1
|
L
 1.2%
H
7.4
8.1
|
L
 1.7%
H
7.4
8.2
|
L
 -16.7%
H
7.4
9.3
|
L
 27.8%
H
4.7
9.9
|
L
 -21.8%
H
4.0
11.9
|
L
 3.7%
H
3.8
11.9
|
L
 451.1%
H
1.1
15.0
|
| Kyntra Bio Inc |
|
37.3
|
9.2
|
L
 -3.0%
H
9.2
9.7
|
L
 0.7%
H
8.8
9.8
|
L
 8.5%
H
8.3
10.5
|
L
 -15.9%
H
8.0
11.7
|
L
 -43.4%
H
4.9
22.0
|
L
 -98.1%
H
4.5
642.3
|
L
 -99.0%
H
4.5
1430.2
|
L
 -98.6%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
291.8
|
5.2
|
L
 -1.3%
H
5.0
5.3
|
L
 -0.6%
H
4.6
5.4
|
L
 18.1%
H
4.2
6.0
|
L
 16.7%
H
3.3
6.0
|
L
 11.0%
H
2.9
6.8
|
L
 -17.7%
H
2.7
10.2
|
L
 -73.2%
H
2.7
25.1
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
44.3
|
3.6
|
L
 0.6%
H
3.5
3.7
|
L
 4.7%
H
3.2
3.8
|
L
 11.1%
H
2.7
3.8
|
L
 11.1%
H
1.9
6.4
|
L
 10.1%
H
1.3
6.4
|
L
 -87.9%
H
1.3
53.8
|
L
 -98.4%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Flora Growth Corp |
|
7.6
|
7.3
|
L
 3.1%
H
7.2
7.3
|
L
 6.3%
H
6.7
7.7
|
L
 -22.3%
H
5.9
11.2
|
L
 -61.7%
H
5.9
20.5
|
L
 -81.5%
H
5.9
47
|
L
 -96.2%
H
5.9
464.3
|
L
H
5.9
16731
|
L
H
5.9
16731
|
| Amicus Therapeutics Inc |
|
4,416.8
|
14.3
|
L
H
14.3
14.3
|
L
 0.1%
H
14.2
14.4
|
L
 45.6%
H
9.7
14.4
|
L
 72.7%
H
7.9
14.4
|
L
 54.4%
H
5.5
14.4
|
L
 26.4%
H
5.5
14.6
|
L
 -38.3%
H
5.5
23.9
|
L
 81.9%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
9.5
|
L
 3.8%
H
9.1
9.6
|
L
 18.0%
H
7.8
9.6
|
L
 31.0%
H
7.2
9.6
|
L
 -79.7%
H
5.2
55.9
|
L
 -37.1%
H
5.2
55.9
|
L
 -94.3%
H
5.2
279.5
|
L
 -99.5%
H
5.2
2918.5
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
649.8
|
9.9
|
L
 -2.6%
H
9.8
10.4
|
L
 -9.8%
H
9.8
11.0
|
L
 -32.5%
H
9.8
15.3
|
L
 2.4%
H
7.3
15.7
|
L
 119.9%
H
2.3
15.7
|
L
 -3.4%
H
2.3
15.7
|
L
 -15.9%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
7.3
|
4.7
|
L
 3.3%
H
4.4
4.7
|
L
 -9.1%
H
4.1
5.3
|
L
 94.6%
H
1.9
5.3
|
L
 0.2%
H
1.9
5.8
|
L
 1011.9%
H
0.4
5.8
|
L
 -96.3%
H
0.4
149.8
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
203.1
|
3.2
|
L
 -1.6%
H
2.9
3.2
|
L
 -22.2%
H
2.9
4.2
|
L
 -47.0%
H
2.9
7.1
|
L
 -33.7%
H
2.9
7.1
|
L
 178.8%
H
1.1
7.1
|
L
 169.2%
H
0.7
7.1
|
L
 41.3%
H
0.7
7.1
|
L
 118.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
88.8
|
2.3
|
L
 -5.3%
H
2.3
2.5
|
L
 -27.4%
H
2.3
3.3
|
L
 -43.0%
H
2.1
4.3
|
L
 11.1%
H
1.7
4.3
|
L
 -5.3%
H
1.4
4.3
|
L
 -29.1%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| Generation Bio Co |
|
36.9
|
5.5
|
L
 -0.5%
H
5.4
5.6
|
L
 0.7%
H
5.3
5.6
|
L
 1.9%
H
5.2
5.8
|
L
 -13.2%
H
4.9
6.9
|
L
 -39.8%
H
3
10.4
|
L
 -88.2%
H
3
73.5
|
L
 -98.0%
H
3
418.6
|
L
H
3
557.2
|
| CytoMed Therapeutics Ltd |
|
15.5
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 -5.0%
H
1.3
1.4
|
L
 -14.8%
H
1.3
1.7
|
L
 -41.3%
H
1.3
3.7
|
L
 -42.4%
H
1.3
3.7
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
| Geron Corp |
|
855.4
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 8.9%
H
1.2
1.5
|
L
 -3.6%
H
1.0
1.5
|
L
 -60.8%
H
1.0
3.5
|
L
 -54.6%
H
1.0
5.3
|
L
 -21.6%
H
1.0
5.3
|
L
 -65.5%
H
0.8
7.0
|
| GH Research PLC |
|
931.1
|
15.0
|
L
 -3.5%
H
14.7
15.8
|
L
 13.4%
H
13.5
19
|
L
 4.9%
H
12.0
19
|
L
 13.9%
H
12.0
19
|
L
 67.2%
H
8.0
20.5
|
L
 71.2%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
150,246.3
|
121.1
|
L
 0.4%
H
119.3
122.8
|
L
 -0.4%
H
116.9
125.1
|
L
 1.5%
H
116.9
127.4
|
L
 3.7%
H
114.0
128.7
|
L
 35.9%
H
88.6
128.7
|
L
 42.3%
H
62.1
128.7
|
L
 92.1%
H
57.2
128.7
|
L
 25.6%
H
56.6
128.7
|
| Galmed Pharma Ltd |
|
4.5
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -28.5%
H
0.7
1.1
|
L
 -46.8%
H
0.7
1.6
|
L
 -71.8%
H
0.7
3.5
|
L
 -99.4%
H
0.2
170.1
|
L
 -99.9%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
350.2
|
25.3
|
L
 12.8%
H
22.1
26.7
|
L
 29.8%
H
18.7
26.7
|
L
 155.6%
H
9.6
30.8
|
L
 126.1%
H
7.8
30.8
|
L
 89.4%
H
7.8
30.8
|
L
 77.2%
H
7.6
30.8
|
L
 -31.7%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Galecto Inc |
|
32.7
|
20.5
|
L
 0.6%
H
19.8
21.4
|
L
 -6.1%
H
19.4
23.9
|
L
 -26.2%
H
19.4
38.3
|
L
 39.0%
H
5.0
38.3
|
L
 288.3%
H
2.0
38.3
|
L
 1127.5%
H
0.5
38.3
|
L
 57.7%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,581.1
|
24.3
|
L
 -4.1%
H
23.9
25.2
|
L
 58.6%
H
13.7
25.8
|
L
 42.9%
H
13.7
25.8
|
L
 187%
H
8.5
25.8
|
L
 305.3%
H
3.5
25.8
|
L
 256.0%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
696.3
|
10.8
|
L
 -1.6%
H
10.6
11.2
|
L
 -2.6%
H
10.6
11.7
|
L
 -22.8%
H
10.6
15.6
|
L
 -12.1%
H
9.8
16.4
|
L
 -61.1%
H
9.8
37
|
L
 -96.1%
H
9.8
416
|
L
 -97.1%
H
9.8
440
|
L
 -97.9%
H
9.8
2605
|
| Genelux Corp |
|
125.2
|
2.8
|
L
 2.9%
H
2.8
2.9
|
L
 -38.5%
H
2.7
5.0
|
L
 -38.5%
H
2.7
5.0
|
L
 -50.6%
H
2.7
8.5
|
L
 9.8%
H
2.0
8.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
5.0
|
2.2
|
L
 10%
H
2.0
2.6
|
L
 22.9%
H
1.7
2.6
|
L
 -32.1%
H
1.7
3.4
|
L
 856.5%
H
0.2
13.0
|
L
 185.7%
H
0.1
13.0
|
L
 65.4%
H
0.1
13.0
|
L
 -41.6%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
578.6
|
2.5
|
L
H
2.4
2.6
|
L
 -13.2%
H
2.4
3.0
|
L
 -27.5%
H
2.4
3.9
|
L
 -2.3%
H
2.1
3.9
|
L
 138.1%
H
0.8
3.9
|
L
 15.7%
H
0.5
3.9
|
L
 -76.3%
H
0.5
15.2
|
L
H
0.5
27.2
|
| Geovax Labs Inc |
|
0.3
|
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -19.1%
H
0.2
0.2
|
L
 -57.5%
H
0.1
0.4
|
L
 -71.7%
H
0.1
0.6
|
L
 -92.3%
H
0.1
2.3
|
L
 -75.7%
H
0.1
11.1
|
L
 -94.8%
H
0.1
11.1
|
L
 -100.0%
H
0.1
1000000
|
| Graphite Bio Inc |
|
866.0
|
14.9
|
L
 -2.4%
H
14.8
15.7
|
L
 -7.1%
H
14.8
17.5
|
L
 -43.8%
H
14.8
26.7
|
L
 -67.9%
H
14.8
46.8
|
L
 -44.5%
H
14.8
50.4
|
L
 -84.2%
H
14.8
413
|
L
H
14.8
1666
|
L
H
14.8
1666
|
| GT Biopharma Inc |
|
7.2
|
0.7
|
L
H
0.6
0.7
|
L
 -17.1%
H
0.6
0.9
|
L
 6.3%
H
0.6
0.9
|
L
 -9.3%
H
0.5
1.2
|
L
 -73.3%
H
0.5
3.9
|
L
 -32%
H
0.2
10.7
|
L
 -92%
H
0.2
19.7
|
L
 -100.0%
H
0.2
18870
|
| Galapagos NV (ADR) |
|
2,181.9
|
33.1
|
L
 0.4%
H
33.0
33.3
|
L
 0.4%
H
31.7
33.9
|
L
 4.7%
H
30.7
33.9
|
L
 -2.7%
H
29.8
35
|
L
 17.5%
H
22.4
37.8
|
L
 -26.6%
H
22.4
48.1
|
L
 -68.0%
H
22.4
113.7
|
L
 -42.1%
H
22.4
274.0
|
| Genmab (ADR) |
|
21,103.9
|
34.3
|
L
 1.9%
H
33.6
34.3
|
L
 7.7%
H
31.3
34.3
|
L
 10.8%
H
30.4
34.3
|
L
 7.6%
H
28.1
34.3
|
L
 54.4%
H
17.2
34.3
|
L
 -19.9%
H
17.2
43.4
|
L
 -17.2%
H
17.2
49.1
|
L
 168.3%
H
9.2
49.1
|
| Genenta Science SpA (ADR) |
|
33.3
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 -20.2%
H
1.3
1.8
|
L
 -57.0%
H
1.3
10
|
L
 -72.1%
H
1.3
10
|
L
 -76.7%
H
1.3
10
|
L
H
1.3
13.1
|
L
H
1.3
13.1
|
| Grifols SA (ADR) - Level III |
|
6,376.4
|
9.4
|
L
 -1.3%
H
9.4
9.5
|
L
 1.4%
H
9.2
9.6
|
L
 6.2%
H
8.7
9.6
|
L
 -1.3%
H
7.6
9.9
|
L
 23.3%
H
6.2
11.1
|
L
 5.0%
H
5.3
12.2
|
L
 -52.2%
H
5.3
20.5
|
L
 -39.2%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
8,522.3
|
72.5
|
L
 0.5%
H
72.0
73.4
|
L
 3.1%
H
69.2
75.6
|
L
 17.1%
H
61.2
75.6
|
L
 11.3%
H
61.2
75.6
|
L
 38.8%
H
47.5
79.5
|
L
 31.7%
H
29.9
79.5
|
L
 66.3%
H
29.9
79.5
|
L
 388.0%
H
7.0
79.5
|
| HCW Biologics Inc |
|
3.3
|
1.2
|
L
H
1.2
1.3
|
L
 8.9%
H
1.1
1.4
|
L
 -36.5%
H
1.0
2.2
|
L
 -73.1%
H
1.0
4.6
|
L
 -92.4%
H
0.2
41.2
|
L
 -98.5%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
32.8
|
2.8
|
L
 -4.1%
H
2.8
3.0
|
L
 -17.5%
H
2.8
3.4
|
L
 7.3%
H
2.2
3.6
|
L
 -11.7%
H
2.2
6.9
|
L
 109.8%
H
1.1
9.1
|
L
 -72.8%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
16.8
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 0.9%
H
1.0
1.1
|
L
 -9.2%
H
1.0
1.3
|
L
 -35.3%
H
1.0
1.7
|
L
 -43.2%
H
0.7
2.5
|
L
 -83.4%
H
0.6
7.8
|
L
 -97.9%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
29.1
|
0.6
|
L
 -4.8%
H
0.6
0.7
|
L
 -6.3%
H
0.6
0.7
|
L
 -40.6%
H
0.6
1.2
|
L
 -66.3%
H
0.6
1.9
|
L
 -58.3%
H
0.6
2.4
|
L
 -71.2%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,220.3
|
38.6
|
L
 1.8%
H
37.0
38.8
|
L
 3.1%
H
35.4
38.8
|
L
 -0.7%
H
35.4
40.9
|
L
 44.0%
H
25.5
40.9
|
L
 11.6%
H
25.5
40.9
|
L
 -14.4%
H
18.6
51.3
|
L
 4.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,732.6
|
46.8
|
L
 -8.4%
H
46.5
51.1
|
L
 -6.3%
H
46.5
54.9
|
L
 -3.3%
H
44
54.9
|
L
 15.3%
H
32.6
54.9
|
L
 29.4%
H
20.9
54.9
|
L
 238.0%
H
7.6
59.2
|
L
 505.2%
H
5.4
59.2
|
L
 642.5%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
254.9
|
1.4
|
L
 9.5%
H
1.3
1.6
|
L
 10.3%
H
1.2
1.6
|
L
 4.5%
H
1.1
1.6
|
L
 6.1%
H
1
1.6
|
L
 -13.1%
H
1
2.7
|
L
 -46.1%
H
0.5
3.9
|
L
 -92.9%
H
0.5
20.5
|
L
 -94.1%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
26.6
|
6.9
|
L
 -4.6%
H
6.9
7.5
|
L
 -1.1%
H
6.9
7.7
|
L
 -34.8%
H
6.5
11.5
|
L
 -54.7%
H
5.6
16.4
|
L
 84.3%
H
2.9
38.3
|
L
 -87.4%
H
2.7
136.5
|
L
 -94.4%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
225.8
|
1.2
|
L
H
1.2
1.2
|
L
 19.4%
H
1.0
1.3
|
L
 -7.9%
H
0.9
1.3
|
L
 -28.7%
H
0.9
1.9
|
L
 -75%
H
0.9
4.9
|
L
 -49.1%
H
0.9
10.0
|
L
 -88.5%
H
0.9
17.5
|
L
H
0.9
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,530.4
|
14.7
|
L
 -0.3%
H
14.7
14.9
|
L
 7.8%
H
13.2
15
|
L
 7.3%
H
13.1
15
|
L
 -8.1%
H
13.1
16.0
|
L
 -3.4%
H
11.5
19.5
|
L
 -13.8%
H
10.7
21.9
|
L
 -60%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
2,295.0
|
2.3
|
L
 4.0%
H
2.3
2.4
|
L
 15.4%
H
2.0
2.4
|
L
 5.0%
H
2.0
2.5
|
L
 -4.5%
H
2.0
2.7
|
L
 -9.0%
H
1.8
4.3
|
L
 -45.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Immucell Corp |
|
58.8
|
6.5
|
L
 -1.1%
H
6.5
6.9
|
L
 9.8%
H
5.8
6.9
|
L
 16.7%
H
5.5
7.1
|
L
 -3.3%
H
4.5
7.1
|
L
 25.7%
H
4.3
7.6
|
L
 -0.8%
H
3.3
7.8
|
L
 4.3%
H
3.3
13.2
|
L
 -17.6%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
3,277.0
|
37.4
|
L
 2.6%
H
36.6
38.0
|
L
 10.4%
H
32.6
39.3
|
L
 9.7%
H
32.6
39.3
|
L
 39.5%
H
26.1
39.3
|
L
 50.4%
H
13.5
39.3
|
L
 123.3%
H
13.3
47.7
|
L
 167.2%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
70.5
|
1.0
|
L
 -4.6%
H
1.0
1.1
|
L
 -4.6%
H
1.0
1.2
|
L
 -1.9%
H
1.0
1.2
|
L
 -28.8%
H
0.9
1.9
|
L
 -55.4%
H
0.7
2.8
|
L
 -60.6%
H
0.7
7.3
|
L
 -81.8%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
77.6
|
6.9
|
L
 1.3%
H
6.9
7.1
|
L
 2.7%
H
6.3
7.1
|
L
 5.0%
H
5.7
7.2
|
L
 -15.7%
H
5.7
9.1
|
L
 -63.9%
H
5.7
19.3
|
L
 -81.7%
H
5.7
91.7
|
L
H
5.7
451.3
|
L
H
5.7
451.3
|
| Inhibikase Therapeutics Inc |
|
208.6
|
1.7
|
L
 3.0%
H
1.7
1.8
|
L
 -11.8%
H
1.7
2.2
|
L
 17.8%
H
1.4
2.2
|
L
 3.6%
H
1.3
2.2
|
L
 -44.5%
H
1.3
3.3
|
L
 -50.6%
H
0.8
6.9
|
L
 -96.1%
H
0.8
55.0
|
L
H
0.8
70.8
|
| Illumina Inc |
|
21,555.5
|
141.1
|
L
 -3.3%
H
139.8
145.8
|
L
 5%
H
134.4
151.3
|
L
 6.8%
H
129.3
151.3
|
L
 46.3%
H
88
151.3
|
L
 1.6%
H
68.7
153.1
|
L
 -32.0%
H
68.7
238.6
|
L
 -62.8%
H
68.7
555.8
|
L
 -14.6%
H
68.7
555.8
|
| IM Cannabis Corp |
|
7.5
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -4.7%
H
1.4
1.6
|
L
 -14.5%
H
1.3
2.1
|
L
 -27.2%
H
0.9
2.6
|
L
 -43.0%
H
0.9
7.1
|
L
 -81.0%
H
0.4
11.0
|
L
 -99.7%
H
0.4
697.8
|
L
H
0.4
697.8
|
| Immix Biopharma Inc |
|
256.6
|
4.9
|
L
 -4.3%
H
4.7
5.1
|
L
 -10.3%
H
4.7
5.6
|
L
 -26.2%
H
4.7
7.7
|
L
 88.8%
H
2.3
7.7
|
L
 116.4%
H
1.3
7.7
|
L
 131.9%
H
1.3
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immunome Inc |
|
2,324.8
|
21.1
|
L
 3.0%
H
20.7
22.0
|
L
 1.2%
H
19.2
22.0
|
L
 10.6%
H
18.8
25.3
|
L
 47.5%
H
13.5
25.3
|
L
 97.7%
H
5.2
25.3
|
L
 428.1%
H
3.8
31.0
|
L
 81.6%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
12.5
|
3.7
|
L
 -4.4%
H
3.7
4.0
|
L
 -6.6%
H
3.7
4.2
|
L
 -7.1%
H
3.0
4.4
|
L
 -29.0%
H
3.0
5.4
|
L
 -73.0%
H
3.0
47.4
|
L
 -84.6%
H
3.0
54.8
|
L
 -98.1%
H
3.0
783
|
L
 -99.9%
H
3.0
5922
|
| Immuneering Corp (Class A) |
|
300.9
|
4.7
|
L
 -1.5%
H
4.2
4.9
|
L
 -29.6%
H
4.2
8.5
|
L
 -25.3%
H
4.2
8.5
|
L
 -25.3%
H
4.2
8.5
|
L
 133%
H
1.1
10.1
|
L
 5.4%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,229.4
|
9.2
|
L
 -1.6%
H
9.1
9.5
|
L
 -12.3%
H
9.1
10.6
|
L
 -9.0%
H
9.1
10.9
|
L
 -15.9%
H
8.7
12.4
|
L
 31.6%
H
3.3
12.4
|
L
 6.4%
H
3.3
13.8
|
L
 -16.6%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunic Inc |
|
79.4
|
0.7
|
L
H
0.7
0.7
|
L
 13.8%
H
0.6
0.7
|
L
 -1.5%
H
0.5
0.7
|
L
 -28.3%
H
0.5
0.9
|
L
 -40%
H
0.5
1.4
|
L
 -52.9%
H
0.5
3.2
|
L
 -96.3%
H
0.5
28.2
|
L
 -99.8%
H
0.5
390
|
| Immunovant Inc |
|
5,244.4
|
26.0
|
L
 -1.1%
H
26
27.8
|
L
 0.5%
H
24.7
27.8
|
L
 14.4%
H
22.3
27.8
|
L
 48.9%
H
16.6
27.8
|
L
 10.2%
H
12.7
27.8
|
L
 38.9%
H
12.7
45.6
|
L
 -47.5%
H
3.1
50.3
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
22.9
|
2.4
|
L
 -2.1%
H
2.2
2.6
|
L
 -4.5%
H
2.2
2.6
|
L
 36.6%
H
1.2
2.6
|
L
 0.9%
H
1.2
2.6
|
L
 658.1%
H
0.1
4.2
|
L
 -14.5%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,452.0
|
72.9
|
L
 -3.1%
H
72.2
76.4
|
L
 -2.9%
H
72.2
80
|
L
 -18.0%
H
72.2
94.6
|
L
 108.2%
H
28.2
94.6
|
L
 386.4%
H
10.8
94.6
|
L
 216.4%
H
10.8
94.6
|
L
 113.4%
H
7.7
94.6
|
L
H
7.7
94.6
|
| Incyte |
|
20,981.0
|
106.9
|
L
 0.9%
H
105.9
107.7
|
L
 5.4%
H
99.0
112.3
|
L
 12.3%
H
93.5
112.3
|
L
 26.1%
H
82.8
112.3
|
L
 46.1%
H
53.6
112.3
|
L
 35.6%
H
50.3
112.3
|
L
 13.9%
H
50.3
112.3
|
L
 12.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
5.5
|
3.1
|
L
 4.3%
H
2.9
3.2
|
L
 14.2%
H
2.4
3.2
|
L
 20.4%
H
1.9
3.2
|
L
 -27.4%
H
1.7
4.8
|
L
 222.7%
H
0.3
13.4
|
L
 95.6%
H
0.3
13.4
|
L
 -79.9%
H
0.3
36.8
|
L
 -99.2%
H
0.3
8800
|
| Indivior PLC |
|
4,430.9
|
35.4
|
L
 -0.2%
H
33.8
35.8
|
L
 -0.8%
H
33.8
37.7
|
L
 -1.6%
H
33.8
37.7
|
L
 46.8%
H
23.0
38
|
L
 193.1%
H
7.6
38
|
L
 61.4%
H
7.3
38
|
L
 2431.4%
H
1.4
38
|
L
 1263.1%
H
0.4
38
|
| MiNK Therapeutics Inc |
|
58.2
|
12.4
|
L
H
12.3
12.7
|
L
 11.5%
H
11.0
12.7
|
L
 -4.5%
H
10.8
13.3
|
L
 -14.8%
H
10.5
15.4
|
L
 59.0%
H
0.9
76
|
L
 -46.6%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
3.6
|
1.3
|
L
 3.2%
H
1.3
1.4
|
L
 15.2%
H
1.1
1.4
|
L
 -1.5%
H
1.0
1.5
|
L
 -45.1%
H
1.0
2.4
|
L
 -71.4%
H
1.0
8.3
|
L
 -96.2%
H
1.0
55.4
|
L
 -99.9%
H
1.0
3210
|
L
 -99.9%
H
1.0
32175
|
| INmune Bio Inc |
|
39.6
|
1.5
|
L
 -2.6%
H
1.5
1.5
|
L
 -3.3%
H
1.5
1.7
|
L
 -31.3%
H
1.5
2.3
|
L
 -24.8%
H
1.4
2.3
|
L
 -71.9%
H
1.4
11.6
|
L
 -78.7%
H
1.4
14.7
|
L
 -91.8%
H
1.4
30.4
|
L
H
1.4
30.4
|
| Inovio Pharma Inc |
|
107.2
|
1.6
|
L
 -3.1%
H
1.5
1.7
|
L
 -7.7%
H
1.5
1.7
|
L
 -28.4%
H
1.5
2.7
|
L
 -41.1%
H
1.5
2.7
|
L
 -28.1%
H
1.3
3.0
|
L
 -1.9%
H
0.3
14.8
|
L
 -83.1%
H
0.3
19
|
L
 -72.9%
H
0.3
33.8
|
| Insmed Inc |
|
37,529.7
|
176.0
|
L
 3.4%
H
169
186.2
|
L
 -0.7%
H
167.4
186.2
|
L
 -9.4%
H
161.0
205.2
|
L
 7.0%
H
154.8
212.8
|
L
 167.8%
H
60.4
212.8
|
L
 889.2%
H
16.0
212.8
|
L
 423.3%
H
16.0
212.8
|
L
 994.3%
H
9.0
212.8
|
| Innoviva Inc |
|
1,464.0
|
19.6
|
L
 -0.4%
H
19.5
20.0
|
L
 -1.5%
H
19.3
20.2
|
L
 -5.5%
H
19.3
21.1
|
L
 12.2%
H
16.5
22.8
|
L
 13.1%
H
16.5
22.8
|
L
 49.7%
H
10.6
22.8
|
L
 52.1%
H
10.6
22.8
|
L
 99.6%
H
7.6
22.8
|
| IO Biotech Inc |
|
40.3
|
0.6
|
L
H
0.6
0.6
|
L
 -16.4%
H
0.6
0.7
|
L
 -34.1%
H
0.6
0.9
|
L
 5.7%
H
0.6
1.2
|
L
 -34.9%
H
0.3
2.8
|
L
 -77.1%
H
0.3
3.3
|
L
H
0.3
17.9
|
L
H
0.3
17.9
|
| Ionis Pharma Inc |
|
13,006.5
|
80.3
|
L
 -1.5%
H
79.3
83.2
|
L
 0.8%
H
76.1
86.2
|
L
 1.8%
H
76.1
86.2
|
L
 14.3%
H
66.7
86.2
|
L
 135.5%
H
24.0
86.2
|
L
 115.6%
H
24.0
86.2
|
L
 31.6%
H
24.0
86.2
|
L
 41.2%
H
19.6
86.6
|
| Iovance Biotherapeutics Inc |
|
972.6
|
2.5
|
L
 -6.1%
H
2.4
2.7
|
L
 -2.8%
H
2.4
2.8
|
L
 8.9%
H
2.1
3.0
|
L
 11.9%
H
1.8
3.0
|
L
 -65.8%
H
1.6
7
|
L
 -60.2%
H
1.6
18.3
|
L
 -95.2%
H
1.6
54.2
|
L
 -62.7%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
169.6
|
1.9
|
L
 9.6%
H
1.7
2.0
|
L
 94%
H
0.9
2.0
|
L
 228.8%
H
0.5
2.0
|
L
 223.3%
H
0.4
2.0
|
L
 81.3%
H
0.3
2.0
|
L
 -59.4%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,949.8
|
78.1
|
L
 -1.5%
H
77.8
80.5
|
L
 -1.2%
H
76.2
81.9
|
L
 -14.8%
H
71.4
94.5
|
L
 10.5%
H
68.8
99.5
|
L
 24.9%
H
30.8
99.5
|
L
 307.0%
H
18.2
99.5
|
L
 -35.5%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
660.5
|
4.1
|
L
 2.0%
H
3.9
4.1
|
L
 -4.9%
H
3.9
5.0
|
L
 12.5%
H
3.1
5.8
|
L
 129.4%
H
1.4
5.8
|
L
 -11.4%
H
0.5
5.8
|
L
 -63.7%
H
0.5
15.7
|
L
 -65.8%
H
0.5
15.7
|
L
 -55.1%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
17.6
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 3.1%
H
0.3
0.4
|
L
 -26.7%
H
0.3
0.5
|
L
 -59.3%
H
0.3
0.8
|
L
 -81.7%
H
0.3
1.9
|
L
 -66.3%
H
0.3
3.0
|
L
 -98.2%
H
0.3
44.9
|
L
H
0.3
195
|
| Invivyd Inc |
|
710.6
|
2.5
|
L
 0.4%
H
2.5
2.8
|
L
 0.8%
H
2.4
2.8
|
L
 1.6%
H
2.2
3.0
|
L
 33.3%
H
1.4
3.1
|
L
 447.8%
H
0.4
3.1
|
L
 40.8%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
426.5
|
3.7
|
L
 -2.4%
H
3.6
3.8
|
L
 -13.4%
H
3.6
5.2
|
L
 -8.0%
H
3.6
5.2
|
L
 -23.7%
H
3.6
6.8
|
L
 236.4%
H
0.6
6.8
|
L
 -34.2%
H
0.6
7.7
|
L
 -93.6%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,667.5
|
33
|
L
 -0.2%
H
32.8
34.0
|
L
 -2.3%
H
32.5
35.8
|
L
 -9.9%
H
32.5
38.4
|
L
 -2.3%
H
30.5
40.7
|
L
 9.2%
H
23.2
40.7
|
L
 -35.8%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
434.2
|
3.0
|
L
 -1.0%
H
2.9
3.0
|
L
H
2.8
3.1
|
L
 31.1%
H
2.3
3.3
|
L
 45.3%
H
1.7
3.5
|
L
 47.5%
H
1.3
3.5
|
L
 55.3%
H
1.3
3.9
|
L
 -10.6%
H
1.3
5.4
|
L
 -19.6%
H
0.5
8.0
|
| Immuron Ltd (ADR) |
|
6.9
|
0.9
|
L
 3.7%
H
0.9
0.9
|
L
 6.3%
H
0.8
0.9
|
L
 -43.7%
H
0.7
1.2
|
L
 -60.3%
H
0.7
2.4
|
L
 -58.1%
H
0.7
2.4
|
L
 -57.9%
H
0.7
6.0
|
L
 -87.6%
H
0.7
9.2
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
164.9
|
1.8
|
L
 1.2%
H
1.7
1.9
|
L
 -3.3%
H
1.7
1.9
|
L
 -6.9%
H
1.6
1.9
|
L
 -13.3%
H
1.6
2.4
|
L
 -3.8%
H
1.6
2.6
|
L
 -47.6%
H
1.3
4.0
|
L
 -62.2%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Inventiva (ADR) |
|
922.6
|
4.8
|
L
 -1.8%
H
4.8
4.9
|
L
 1.5%
H
4.5
5.2
|
L
 13.4%
H
4.1
5.2
|
L
 -12.7%
H
3.6
8.0
|
L
 117.6%
H
2.1
8.0
|
L
 -7.1%
H
1.5
8.0
|
L
 -67.6%
H
1.5
19.1
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
4.4
|
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 5%
H
1.0
1.1
|
L
 -10.3%
H
0.9
1.5
|
L
 -54.4%
H
0.9
2.4
|
L
 -3.7%
H
0.4
15.5
|
L
 -99.7%
H
0.4
549
|
L
 -100.0%
H
0.4
56700
|
L
 -100.0%
H
0.4
999999
|
| Janux Therapeutics Inc |
|
851.7
|
14.2
|
L
 1.8%
H
13.9
14.3
|
L
 3.7%
H
13.3
14.3
|
L
 -10.0%
H
13.3
15.8
|
L
 -45.2%
H
13.3
35.3
|
L
 -72.1%
H
13.3
50.9
|
L
 -0.6%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
9,791.1
|
161.1
|
L
 0.6%
H
159.9
165.6
|
L
 -6.9%
H
157.0
175.8
|
L
 -0.7%
H
157.0
175.8
|
L
 16.6%
H
128.8
183.0
|
L
 32.6%
H
95.5
183.0
|
L
 5.5%
H
95.5
183.0
|
L
 -0.2%
H
95.5
189
|
L
 25.9%
H
86.9
189
|
| Jasper Therapeutics Inc |
|
42.3
|
1.5
|
L
 -9.0%
H
1.5
1.7
|
L
 -17.9%
H
1.5
2.1
|
L
 -14.7%
H
1.5
2.1
|
L
 -39.4%
H
1.4
2.7
|
L
 -78.4%
H
1.4
7.4
|
L
 -5.0%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
17.5
|
0.6
|
L
 -3.1%
H
0.6
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -20.3%
H
0.5
0.8
|
L
 -59.4%
H
0.5
1.9
|
L
 -90.8%
H
0.5
20.6
|
L
 -97.6%
H
0.5
29.0
|
L
 -99.8%
H
0.5
498.5
|
L
H
0.5
1337.5
|
| KalVista Pharma Inc |
|
849.2
|
16.8
|
L
 6.2%
H
16.0
19
|
L
 8.7%
H
15.1
19
|
L
 4.0%
H
14.7
19
|
L
 42.3%
H
10.4
19
|
L
 103.9%
H
7.3
19
|
L
 154.5%
H
6.3
19
|
L
 1.0%
H
4.1
45
|
L
 -59.2%
H
4.1
45
|
| Kamada Ltd |
|
463.8
|
8.0
|
L
 1.1%
H
8.0
8.1
|
L
 14.4%
H
7.2
8.1
|
L
 18.1%
H
6.9
8.1
|
L
 16.0%
H
6.6
8.1
|
L
 9.8%
H
5.5
9.2
|
L
 71.1%
H
4.1
9.2
|
L
 21.6%
H
3.7
9.2
|
L
 94.2%
H
3.3
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,234.2
|
42.7
|
L
 2.3%
H
41.3
42.7
|
L
 1.6%
H
39.2
43.6
|
L
 3.7%
H
39.2
44.4
|
L
 12.0%
H
35.2
44.4
|
L
 110.2%
H
17.8
44.4
|
L
 193.1%
H
10.3
44.4
|
L
 124.8%
H
7.4
44.4
|
L
H
5.0
44.4
|
| Kodiak Sciences Inc |
|
1,692.3
|
27.7
|
L
 4.1%
H
26.5
27.8
|
L
 6.5%
H
23.9
28.1
|
L
 10.7%
H
21.5
31.2
|
L
 104.6%
H
10.9
31.2
|
L
 201.3%
H
1.9
31.2
|
L
 236.8%
H
1.4
31.2
|
L
 -82.0%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
7.9
|
2.2
|
L
 -1.4%
H
2.1
2.3
|
L
 6.4%
H
2.0
2.3
|
L
 4.4%
H
1.9
2.3
|
L
 -23.8%
H
1.8
2.9
|
L
 -42.4%
H
1.8
4.2
|
L
 -39.4%
H
0.4
8.5
|
L
 -99.0%
H
0.4
314
|
L
 -99.8%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
148.0
|
8.7
|
L
 6.2%
H
8.1
9.0
|
L
 20.7%
H
7.1
9.0
|
L
 35.8%
H
6.0
9.0
|
L
 49.1%
H
5.0
9.0
|
L
 -19.2%
H
0.6
11.4
|
L
 -79.6%
H
0.6
73.1
|
L
 -96.7%
H
0.6
260.9
|
L
 -93.9%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
584.9
|
19.2
|
L
 3.3%
H
18.7
19.5
|
L
 3.6%
H
17.5
19.5
|
L
 -10.8%
H
17.5
22.2
|
L
 19.1%
H
13.6
22.6
|
L
 29.0%
H
9.1
22.6
|
L
 -58.6%
H
9.1
73
|
L
 -72.9%
H
9.1
76.0
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
7,580.2
|
261.4
|
L
 5.0%
H
252.9
267.5
|
L
 5.9%
H
235.6
267.5
|
L
 11.4%
H
231.7
267.5
|
L
 38.5%
H
179.2
267.5
|
L
 66.9%
H
122.8
267.5
|
L
 254.1%
H
69.8
267.5
|
L
 294.1%
H
38.9
267.5
|
L
H
8.0
267.5
|
| TuHURA Biosciences Inc |
|
42.4
|
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
H
0.7
0.8
|
L
 -35.9%
H
0.7
1.2
|
L
 -70.9%
H
0.7
2.6
|
L
 -82.0%
H
0.7
5.5
|
L
 -99.7%
H
0.2
279.3
|
L
 -100.0%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
21.5
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 -21.9%
H
0.8
1.2
|
L
 -20.5%
H
0.8
1.3
|
L
 17.7%
H
0.3
2.1
|
L
 -66.8%
H
0.3
3.9
|
L
 55%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
818.8
|
9.4
|
L
 -1.5%
H
9.4
9.7
|
L
 -9.0%
H
9.2
10.4
|
L
 -11.8%
H
9.2
11.3
|
L
 -8.2%
H
8.8
12.5
|
L
 21.0%
H
5.4
12.5
|
L
 -21.1%
H
5.4
24.2
|
L
 -76.0%
H
5.4
39
|
L
 34.8%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
5,981.5
|
74.8
|
L
 -0.3%
H
74.6
77.9
|
L
 2.8%
H
69.1
77.9
|
L
 -13.9%
H
69.1
93.8
|
L
 31.1%
H
55.3
103
|
L
 84.5%
H
19.4
103
|
L
 176.6%
H
9.6
103
|
L
 -3.1%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
45.4
|
6.2
|
L
 -4.6%
H
6.0
6.3
|
L
 -1.4%
H
6.0
6.5
|
L
 -0.8%
H
6.0
6.5
|
L
 40.9%
H
4.1
6.5
|
L
 -5.8%
H
3.5
6.8
|
L
 -90.2%
H
0.7
74.4
|
L
 -88.6%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics Ltd (ADR) |
|
77.3
|
6.8
|
L
 0.6%
H
6.5
7.1
|
L
 36.4%
H
5.3
7.1
|
L
 -56.2%
H
5
15.6
|
L
 -5.0%
H
5
17.4
|
L
 -19.3%
H
2.9
17.4
|
L
 -83.3%
H
2.9
84
|
L
 -98.6%
H
2.9
744.5
|
L
 -98.5%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
18.7
|
0.8
|
L
 7.1%
H
0.7
0.8
|
L
 15.4%
H
0.6
0.8
|
L
 -33.6%
H
0.5
1.4
|
L
 -15.7%
H
0.5
1.4
|
L
 -66.1%
H
0.5
2.3
|
L
 -71.2%
H
0.5
6.9
|
L
 -90.1%
H
0.5
12.5
|
L
 -83.3%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
283.2
|
7.6
|
L
 -2.7%
H
7.5
7.8
|
L
 -2.3%
H
7.5
8.4
|
L
 -0.4%
H
7.3
8.8
|
L
 14.0%
H
6.3
8.8
|
L
 30.3%
H
4.8
8.9
|
L
 19.1%
H
1.5
11.5
|
L
 -29.6%
H
1.5
12.9
|
L
 -32.6%
H
1.5
15.6
|
| Lifevantage Corp |
|
82.4
|
6.5
|
L
 2.4%
H
6.3
6.6
|
L
 7.6%
H
6
6.6
|
L
 -1.2%
H
5.7
6.7
|
L
 -30.8%
H
5.7
9.5
|
L
 -70.0%
H
5.7
27.4
|
L
 73.1%
H
3.0
27.4
|
L
 -32.3%
H
3.0
27.4
|
L
 -18.1%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
4,067.2
|
206.7
|
L
 3.3%
H
197.9
206.9
|
L
 8.7%
H
187.1
206.9
|
L
 11.2%
H
179.7
206.9
|
L
 13.3%
H
177.4
212.5
|
L
 86.9%
H
93.6
212.5
|
L
 208.3%
H
49.3
212.5
|
L
 201.2%
H
46.8
212.5
|
L
 227.0%
H
36.9
212.5
|
| Longeveron Inc (Class A) |
|
13.2
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 5.1%
H
0.6
0.6
|
L
 -4.6%
H
0.5
0.6
|
L
 -29.6%
H
0.5
0.9
|
L
 -65.8%
H
0.5
1.9
|
L
 -98.1%
H
0.5
45.8
|
L
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
69.6
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -6.6%
H
0.7
0.8
|
L
 -12.4%
H
0.7
0.9
|
L
 -25.3%
H
0.6
1.1
|
L
 -81.0%
H
0.6
7.3
|
L
 -70.4%
H
0.6
7.3
|
L
 -82.2%
H
0.6
13.1
|
L
 -99.3%
H
0.6
126.6
|
| Lixte biotech Holdings Inc |
|
31.8
|
3.7
|
L
 -2.7%
H
3.6
3.8
|
L
 -5.0%
H
3.5
4.0
|
L
 -13.3%
H
3.5
4.4
|
L
 -24.0%
H
3.5
5.0
|
L
 58.7%
H
0.6
6.3
|
L
 -35.4%
H
0.6
27
|
L
 -88.9%
H
0.6
71.9
|
L
 -82.6%
H
0.6
110.4
|
| Lipocine Inc |
|
44.5
|
8.0
|
L
 6.4%
H
7.4
8.1
|
L
 0.1%
H
6.9
8.1
|
L
 145.0%
H
3.1
8.4
|
L
 154.3%
H
2.5
8.4
|
L
 53.2%
H
2.5
8.4
|
L
 -1.8%
H
2.3
11.8
|
L
 -69.4%
H
2.3
41.1
|
L
 -95.9%
H
2.3
215.2
|
| Leap Therapeutics Inc |
|
61.2
|
1.1
|
L
 -6.9%
H
1.1
1.2
|
L
 -4.4%
H
0.9
1.2
|
L
 -33.3%
H
0.9
1.7
|
L
 56.5%
H
0.4
3.7
|
L
 -68.1%
H
0.2
3.7
|
L
 -79.0%
H
0.2
10.2
|
L
 -95.2%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
3,119.7
|
35.9
|
L
 12.9%
H
29.4
38.2
|
L
 14.2%
H
29.3
38.2
|
L
 5.4%
H
29.3
38.2
|
L
 47.9%
H
21.9
38.2
|
L
 187.8%
H
11.3
38.2
|
L
 519.3%
H
5.7
38.2
|
L
 1095.3%
H
2.3
38.2
|
L
H
2.3
38.5
|
| Larimar Therapeutics Inc |
|
276.7
|
3.3
|
L
 -0.9%
H
3.3
3.5
|
L
 -4.0%
H
3.3
3.5
|
L
 -17.4%
H
3.3
4.2
|
L
 -26.8%
H
3.1
4.5
|
L
 -12.1%
H
1.6
5.4
|
L
 -24.7%
H
1.6
13.7
|
L
 -82.6%
H
1.5
20.8
|
L
 -95.3%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
17.4
|
2.0
|
L
 -4.4%
H
2.0
2.1
|
L
 0.5%
H
1.9
2.1
|
L
 -1.5%
H
1.8
2.2
|
L
 -18.9%
H
1.8
3.0
|
L
 -48.2%
H
1.8
4.1
|
L
 -34.3%
H
1.8
4.5
|
L
 -91.8%
H
1.8
73.4
|
L
 -97.5%
H
1.8
199.5
|
| Lantern Pharma Inc |
|
39.0
|
3.5
|
L
 3.0%
H
3.4
3.6
|
L
 12.2%
H
3.1
3.6
|
L
 -10.1%
H
2.9
4.0
|
L
 -24.5%
H
2.9
4.7
|
L
 -11.0%
H
2.6
6.1
|
L
 -36.5%
H
2.4
12.0
|
L
 -81.5%
H
2.4
23.5
|
L
H
2.4
24.8
|
| Lexicon Pharma Inc |
|
425.2
|
1.2
|
L
 -0.9%
H
1.2
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 -10.7%
H
1.1
1.4
|
L
 -28.7%
H
1.1
1.7
|
L
 36.1%
H
0.3
1.7
|
L
 -44.5%
H
0.3
3.8
|
L
 -69.5%
H
0.3
9.7
|
L
 -89.6%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
521.5
|
24.6
|
L
 1.0%
H
24.3
25.8
|
L
 -15.3%
H
24.3
29.2
|
L
 -16.1%
H
24.3
45
|
L
 30.1%
H
15.7
45
|
L
 88.3%
H
7.7
45
|
L
 -61.6%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Lyra Therapeutics Inc |
|
6.7
|
3.8
|
L
 -0.8%
H
3.7
3.9
|
L
 19.3%
H
3.1
3.9
|
L
 -4.8%
H
3.0
4.3
|
L
 -52.7%
H
2.8
8.1
|
L
 -62.5%
H
2.8
37.5
|
L
 -97.3%
H
2.8
339.5
|
L
 -99.3%
H
2.8
825
|
L
H
2.8
1100
|
| Legend Biotech Corp (ADR) |
|
4,358.7
|
23.6
|
L
 2.5%
H
23.1
24.1
|
L
 9.7%
H
20.2
24.1
|
L
 -1.2%
H
20.2
24.2
|
L
 -26.8%
H
20.2
34.8
|
L
 -28.0%
H
20.2
45.3
|
L
 -49.4%
H
20.2
77.3
|
L
 -20.2%
H
20.2
77.3
|
L
H
20.2
77.3
|
| Mustang Bio Inc |
|
8.5
|
1.2
|
L
 1.8%
H
1.2
1.2
|
L
 8.4%
H
1.0
1.2
|
L
 -7.9%
H
0.9
1.3
|
L
 -34.5%
H
0.9
1.8
|
L
 -89.6%
H
0.1
13.3
|
L
 -99.7%
H
0.1
554.2
|
L
 -100.0%
H
0.1
3915
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
140.4
|
2.1
|
L
 -4.6%
H
2.1
2.2
|
L
 -1.0%
H
2.1
2.2
|
L
 -15.0%
H
2.0
2.6
|
L
 -34.1%
H
1.7
3.2
|
L
 11.8%
H
1.3
4.7
|
L
 -40.5%
H
0.8
4.7
|
L
 -73.7%
H
0.8
10.7
|
L
 -99.7%
H
0.8
729
|
| Moleculin Biotech Inc |
|
12.3
|
4.0
|
L
 -3.2%
H
3.9
4.2
|
L
 9.9%
H
3.6
4.3
|
L
 -40.0%
H
3.1
5.9
|
L
 -69.2%
H
3.1
15.8
|
L
 -91.1%
H
3.1
91.3
|
L
 -99.1%
H
3.1
3318.8
|
L
 -99.8%
H
3.1
3318.8
|
L
H
3.1
21555
|
| Seres Therapeutics Inc |
|
141.6
|
15.7
|
L
 1.3%
H
15.0
15.7
|
L
 3.3%
H
14.5
16.3
|
L
 -6.7%
H
14.0
17.9
|
L
 -19.7%
H
12.5
30.0
|
L
 1741.2%
H
0.4
30.0
|
L
 201.0%
H
0.4
30.0
|
L
 -43.3%
H
0.4
30.0
|
L
 -47.9%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
11,675.0
|
514.1
|
L
 -7.6%
H
511.0
555.1
|
L
 -13.4%
H
511.0
593.0
|
L
 -7.2%
H
511.0
615
|
L
 20.0%
H
393.6
615
|
L
 54.2%
H
265
615
|
L
 79.9%
H
119.8
615
|
L
 344.7%
H
52.3
615
|
L
 5299.8%
H
5.3
615
|
| MediWound Ltd |
|
239.8
|
18.7
|
L
 -3.1%
H
18.7
19.3
|
L
 1.5%
H
18.2
19.7
|
L
 1.3%
H
18.2
19.7
|
L
 4.5%
H
16.7
20.0
|
L
 16.8%
H
14.1
22.5
|
L
 48.9%
H
7.1
24
|
L
 -34.8%
H
7.1
43.5
|
L
 -68.9%
H
7.1
63.6
|
| MEI Pharma Inc |
|
54.1
|
1.5
|
L
 -1.3%
H
1.4
1.5
|
L
 -4.6%
H
1.4
1.7
|
L
 -19.7%
H
1.3
1.9
|
L
 -42.1%
H
1.3
3.0
|
L
 -45.4%
H
1.3
9
|
L
 -75.7%
H
1.3
9
|
L
 -97.6%
H
1.3
91.5
|
L
 -95.1%
H
1.3
102.8
|
| Macrogenics Inc |
|
115.8
|
1.8
|
L
 2.2%
H
1.8
1.9
|
L
 13.7%
H
1.6
1.9
|
L
 31.7%
H
1.3
1.9
|
L
 4.6%
H
1.3
2.2
|
L
 -45.1%
H
1.0
3.4
|
L
 -67.0%
H
1.0
21.9
|
L
 -91.1%
H
1.0
36.5
|
L
 -92.6%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
12.0
|
0.8
|
L
 -21.2%
H
0.8
1.0
|
L
 -8.2%
H
0.8
1.0
|
L
 -36.1%
H
0.5
1.4
|
L
 -64.1%
H
0.5
2.8
|
L
 -71.3%
H
0.5
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
38.2
|
L
 0.2%
H
38.0
39.3
|
L
 -3.8%
H
35.8
40.8
|
L
 -12.4%
H
35.8
44.1
|
L
 9.9%
H
32.2
45.5
|
L
 94.0%
H
16.6
45.5
|
L
 397.3%
H
5.9
45.5
|
L
 -71.7%
H
5.1
227.2
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
596.4
|
7.4
|
L
 1.8%
H
7.2
7.7
|
L
 -5.1%
H
7.2
8.1
|
L
 -12.2%
H
7.2
9.5
|
L
 -15.4%
H
7.2
9.7
|
L
 16.7%
H
4.6
9.7
|
L
 17.1%
H
3.5
9.7
|
L
 -54.9%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
4,474.3
|
86.6
|
L
 6.1%
H
81.6
86.8
|
L
 10.9%
H
73.8
86.8
|
L
 32.4%
H
63.2
86.8
|
L
 17.3%
H
63.2
86.8
|
L
 106.1%
H
36.9
86.8
|
L
 332.4%
H
18.5
86.8
|
L
 337.0%
H
12.8
86.8
|
L
H
6.5
86.8
|
| Milestone Pharma Inc |
|
173.7
|
2.0
|
L
 -6.9%
H
2.0
2.2
|
L
 -0.5%
H
2.0
2.3
|
L
 -22.4%
H
1.6
3.1
|
L
 -2.4%
H
1.6
3.1
|
L
 -7.3%
H
0.6
3.1
|
L
 -44.9%
H
0.6
4.5
|
L
 -71.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,310.0
|
18.5
|
L
 28.9%
H
14.9
18.7
|
L
 54.7%
H
11.1
18.7
|
L
 27.1%
H
11.1
18.7
|
L
 97.1%
H
8.8
18.7
|
L
 -61.6%
H
6.0
62.8
|
L
 52.9%
H
6.0
65.0
|
L
 60.8%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,640.9
|
33.4
|
L
 0.7%
H
32.7
33.9
|
L
 -6.6%
H
32.6
37.7
|
L
 -9.2%
H
32.6
39.2
|
L
 -15.3%
H
32.6
47.7
|
L
 198.0%
H
8.2
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
1,796.4
|
5.9
|
L
 -2.7%
H
5.8
6.1
|
L
 4.5%
H
5.5
6.5
|
L
 1.4%
H
5.5
6.5
|
L
 13.8%
H
4.8
6.5
|
L
 -5.2%
H
3.4
6.5
|
L
 22.6%
H
3.2
7.6
|
L
 72.1%
H
2.5
7.6
|
L
 77.3%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,345.5
|
13.8
|
L
 -5.9%
H
13.8
14.8
|
L
 1.5%
H
13.1
15.3
|
L
 10.7%
H
12
15.3
|
L
 10.7%
H
10.5
15.3
|
L
 95.8%
H
4.7
15.3
|
L
 420.3%
H
2.4
15.3
|
L
 -70.3%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
74.7
|
1.5
|
L
 7.0%
H
1.4
1.5
|
L
 14.3%
H
1.3
1.5
|
L
 -1.3%
H
1.2
1.6
|
L
 24.6%
H
1.2
2.0
|
L
 -23.6%
H
1.1
2.1
|
L
 -37.7%
H
1.1
2.7
|
L
 -73.0%
H
1.1
10.8
|
L
 -61.0%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
421.0
|
63
|
L
 -0.6%
H
61.7
66.6
|
L
 -4.6%
H
56.2
66.6
|
L
 -16.5%
H
56.2
79.3
|
L
 -37.6%
H
56.2
104
|
L
 157.6%
H
24
105
|
L
 388.4%
H
1.4
105
|
L
 101.0%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
33.3
|
2
|
L
 -3.4%
H
2
2.3
|
L
 29.9%
H
1.6
2.5
|
L
 34.2%
H
1.3
2.5
|
L
 90.5%
H
0.8
2.5
|
L
 -30.1%
H
0.8
4.1
|
L
 -37.5%
H
0.7
9.7
|
L
 -88.8%
H
0.7
37.7
|
L
 -97.1%
H
0.7
135.5
|
| Moderna |
|
13,402.2
|
34.3
|
L
 1.3%
H
33.9
35.4
|
L
 11.2%
H
31.3
37.1
|
L
 21.5%
H
28.0
37.1
|
L
 24.6%
H
22.3
37.1
|
L
 -22.1%
H
22.3
45.4
|
L
 -81.4%
H
22.3
207.5
|
L
 -69.6%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
569.9
|
3.9
|
L
 2.1%
H
3.9
4.0
|
L
 15.6%
H
3.4
4.0
|
L
 6.5%
H
3.2
4.0
|
L
 19.1%
H
2.5
4.0
|
L
 -35.9%
H
1.7
6.1
|
L
 -69.7%
H
1.7
16.9
|
L
 -85.1%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
14.7
|
7.7
|
L
 -3.5%
H
7.7
8.1
|
L
 -7.7%
H
7.6
8.3
|
L
 -18.6%
H
6.9
9.4
|
L
 -10.0%
H
6.9
12.5
|
L
 -49.1%
H
6.9
16.5
|
L
 -56.3%
H
6.8
21.2
|
L
 -58.9%
H
6.8
49.1
|
L
 -56.9%
H
6.5
49.1
|
| MaxCyte Inc |
|
152.5
|
1.4
|
L
 -2.7%
H
1.4
1.5
|
L
 -7.7%
H
1.4
1.6
|
L
 -7.1%
H
1.4
1.7
|
L
 -11.7%
H
1.4
1.9
|
L
 -68.7%
H
1.3
5.2
|
L
 -72.1%
H
1.3
6.0
|
L
 -12.3%
H
1.3
17.4
|
L
H
1.3
17.4
|
| TNF Pharma Inc |
|
19.0
|
4.6
|
L
 -2.8%
H
4.5
4.8
|
L
 8.0%
H
4.1
5.1
|
L
 -30.3%
H
3.9
6.6
|
L
 15.1%
H
2.5
8.2
|
L
 -96.4%
H
2.5
152
|
L
 -99.9%
H
2.5
8940
|
L
 -99.9%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
10.7
|
1.2
|
L
H
1.1
1.2
|
L
 1.7%
H
1.1
1.5
|
L
 11.3%
H
1
1.5
|
L
 -22.4%
H
0.9
2.1
|
L
 -70.4%
H
0.9
8.2
|
L
 -99.6%
H
0.9
314
|
L
H
0.9
1200
|
L
H
0.9
1200
|
| Mesoblast Ltd (ADR) |
|
2,697.5
|
21.0
|
L
 5.5%
H
20.1
21.5
|
L
 15.4%
H
18.1
21.5
|
L
 11.7%
H
17.5
21.5
|
L
 7.3%
H
14.1
21.5
|
L
 22%
H
9.6
21.5
|
L
 610.5%
H
1.0
22
|
L
 142.0%
H
1.0
22
|
L
 251.1%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
153.3
|
4.1
|
L
 -3.5%
H
4.1
4.2
|
L
 -2.8%
H
4.1
4.5
|
L
 -4.9%
H
3.9
4.6
|
L
 5.4%
H
3.5
4.8
|
L
 -25.3%
H
3.4
5.9
|
L
 -41.4%
H
3.3
12.7
|
L
 -80.6%
H
3.3
32.0
|
L
 -88.3%
H
3.3
35.3
|
| Mereo Biopharma Grp PLC (ADR) |
|
78.0
|
0.5
|
L
 29.0%
H
0.4
0.5
|
L
 -3.9%
H
0.4
0.6
|
L
 -77.5%
H
0.2
2.4
|
L
 -76.7%
H
0.2
2.4
|
L
 -87.0%
H
0.2
3.8
|
L
 -46.7%
H
0.2
5.0
|
L
 -85.9%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
28.2
|
4.6
|
L
 5.1%
H
4.3
4.6
|
L
 27.0%
H
3.5
4.6
|
L
 46.2%
H
3.1
4.6
|
L
 60.6%
H
2.6
4.6
|
L
 8.1%
H
2.6
4.6
|
L
 -50.2%
H
2.6
10.1
|
L
 -65.1%
H
2.6
19.9
|
L
 -59.4%
H
2.6
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,897.2
|
34.4
|
L
 -4.0%
H
34.4
37.1
|
L
 -2.4%
H
32.7
37.1
|
L
 -1.2%
H
32.7
37.4
|
L
 4.2%
H
32.4
42
|
L
 34.5%
H
14.1
42
|
L
 198.6%
H
5.6
42
|
L
H
5.6
42
|
L
H
5.6
42
|
| Nature`s Sunshine Products Inc |
|
380.2
|
21.7
|
L
 -1.2%
H
21.4
22.1
|
L
 3.6%
H
20.9
22.1
|
L
 1.0%
H
20.9
24.1
|
L
 46.4%
H
13.0
24.1
|
L
 49.4%
H
11.0
24.1
|
L
 138.3%
H
8.3
24.1
|
L
 38.3%
H
7.9
24.1
|
L
 143.6%
H
5.5
24.1
|
| Nautilus biotech Inc |
|
260.2
|
2.1
|
L
 -7.2%
H
2.0
2.2
|
L
 7.9%
H
1.9
2.3
|
L
 1.0%
H
1.8
2.3
|
L
 128.9%
H
0.8
2.5
|
L
 13.2%
H
0.6
2.5
|
L
 10.2%
H
0.6
4.7
|
L
 -81.4%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
13,539.0
|
135.8
|
L
 0.2%
H
134.9
137.1
|
L
 -3.4%
H
134.0
142.2
|
L
 -12.4%
H
134.0
156.7
|
L
 -1.9%
H
133.6
160.2
|
L
 -2.1%
H
84.2
160.2
|
L
 25.7%
H
84.2
160.2
|
L
 21.2%
H
71.9
160.2
|
L
 192.6%
H
31.3
160.2
|
| Minerva Neurosciences Inc |
|
192.6
|
4.5
|
L
 -5.3%
H
4.4
4.8
|
L
 13.5%
H
3.9
4.9
|
L
 14.1%
H
3.6
4.9
|
L
 73.2%
H
2.2
12.5
|
L
 99.6%
H
1.2
12.5
|
L
 168.1%
H
1.2
13.5
|
L
 -78.4%
H
1.2
30
|
L
 -89.8%
H
1.2
126.7
|
| Nektar Therapeutics |
|
807.8
|
39.7
|
L
 -4.2%
H
39.6
41.9
|
L
 -8.5%
H
39.6
45.3
|
L
 -32.4%
H
39.6
59.0
|
L
 -28.6%
H
39.6
66.9
|
L
 129.3%
H
6.5
66.9
|
L
 12.2%
H
6.2
66.9
|
L
 -86.2%
H
6.2
401.3
|
L
 -82.0%
H
6.2
1670.4
|
| Nkarta Inc |
|
148.5
|
2.1
|
L
 -1.0%
H
2.0
2.1
|
L
 11.8%
H
1.8
2.2
|
L
 10%
H
1.7
2.2
|
L
 -11.4%
H
1.7
2.7
|
L
 -12.6%
H
1.3
2.7
|
L
 -60.9%
H
1.3
16.2
|
L
 -96.2%
H
1.3
58.8
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
10.0
|
2.2
|
L
 -0.9%
H
2.1
2.3
|
L
 4.8%
H
2.1
2.7
|
L
 -51.9%
H
1.9
4.7
|
L
 -88.3%
H
1.9
18.6
|
L
 -90.9%
H
1.9
33.7
|
L
 -99.6%
H
1.2
752
|
L
H
1.2
2940
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
17.9
|
L
 -4.1%
H
17.9
19.1
|
L
 -11.1%
H
17.9
20.3
|
L
 -9.2%
H
17.9
23.0
|
L
 -43.2%
H
17.9
37.3
|
L
 -0.4%
H
14.7
37.3
|
L
 62.3%
H
9.8
37.3
|
L
 -93.6%
H
7.5
298
|
L
 -91.1%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.8
|
L
 1.8%
H
7.6
7.8
|
L
 4.3%
H
7.2
7.8
|
L
 9.9%
H
7.1
7.8
|
L
 13.6%
H
6.4
7.8
|
L
 9.0%
H
6.2
7.8
|
L
 251.1%
H
0.0
7.8
|
L
 -72.3%
H
0.0
45.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
18.8
|
8.2
|
L
 -2.6%
H
8.1
8.4
|
L
 -14.6%
H
8.0
9.6
|
L
 -5.6%
H
7.8
12.8
|
L
 -28.0%
H
6.1
14.9
|
L
 -66.1%
H
6.1
24.0
|
L
 -86.7%
H
6.1
83.6
|
L
 -100.0%
H
6.1
17344.8
|
L
H
6.1
1424940
|
| Nurix Therapeutics Inc |
|
1,956.4
|
19.3
|
L
 3.6%
H
18.6
19.3
|
L
 6.9%
H
17.0
19.9
|
L
 -1.3%
H
17.0
20.1
|
L
 77.7%
H
9
22.5
|
L
 -1.1%
H
8.2
22.5
|
L
 88.1%
H
4.2
29.6
|
L
 -52.0%
H
4.2
51.5
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
31.8
|
1.1
|
L
 13.8%
H
0.9
1.1
|
L
 37.2%
H
0.8
1.1
|
L
 12.6%
H
0.7
1.1
|
L
 -14.4%
H
0.7
1.3
|
L
 -4.5%
H
0.7
2.6
|
L
 -13.0%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
65.7
|
2.2
|
L
 -4.7%
H
2.2
2.4
|
L
 -15.3%
H
2.2
2.6
|
L
 -5.5%
H
2.0
2.8
|
L
 -37.6%
H
2.0
3.6
|
L
 -41.0%
H
1.6
6.0
|
L
 -80.9%
H
1.1
54
|
L
 -99.3%
H
1.1
642
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,202.3
|
10.4
|
L
 -1.3%
H
10.1
11.0
|
L
 12.7%
H
9.1
11.0
|
L
 11.6%
H
8.7
11.0
|
L
 -59.2%
H
8.0
28.3
|
L
 -13.6%
H
5.9
28.3
|
L
 -71.5%
H
5.9
47.5
|
L
 -86.8%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,157.9
|
105.1
|
L
 2.3%
H
103.4
106.1
|
L
 4.2%
H
95.5
108.5
|
L
 0.0%
H
95.5
108.5
|
L
 19.4%
H
84.6
112.9
|
L
 34.3%
H
55.5
112.9
|
L
 295.4%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,181.4
|
7.3
|
L
 -1.0%
H
7.3
7.6
|
L
 2.0%
H
7.1
7.8
|
L
 9.2%
H
6.4
7.8
|
L
 -15.4%
H
6.2
9.3
|
L
 -26.0%
H
5.0
10.6
|
L
 -40.7%
H
3.5
23.9
|
L
 -94.0%
H
3.5
331.7
|
L
 -94.9%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
216.7
|
8.5
|
L
 -4.4%
H
8.3
8.9
|
L
 -0.6%
H
8
9.4
|
L
 21.0%
H
6.9
9.4
|
L
 40.8%
H
5.6
9.4
|
L
 37.1%
H
5.3
11.5
|
L
 13.4%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
46.9
|
13.4
|
L
 -1.6%
H
12.9
14.0
|
L
 0.7%
H
12.9
14.1
|
L
 20.0%
H
10.4
14.6
|
L
 104.8%
H
6.2
15.7
|
L
 31.0%
H
2.8
15.7
|
L
 -31.6%
H
2.8
30.8
|
L
 -90.2%
H
2.8
172.8
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
14.0
|
3.4
|
L
 -6.4%
H
3.4
3.7
|
L
 -7.4%
H
3.4
3.8
|
L
 -21.3%
H
3.2
4.6
|
L
 -43.3%
H
3.1
6.2
|
L
 -100.0%
H
2.8
53600
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
| Ocugen Inc |
|
468.5
|
1.5
|
L
 0.7%
H
1.5
1.6
|
L
 8.7%
H
1.3
1.7
|
L
 24.0%
H
1.2
1.7
|
L
 -18.0%
H
1.1
1.8
|
L
 80.7%
H
0.5
1.9
|
L
 20%
H
0.3
2.1
|
L
 -44.2%
H
0.3
18.8
|
L
 -99.2%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,333.6
|
23.1
|
L
 4.7%
H
22.3
24.0
|
L
 15.4%
H
19.7
24.0
|
L
 12.4%
H
19.1
24.0
|
L
 9.2%
H
18.6
24.0
|
L
 23.4%
H
14
24.0
|
L
 128.4%
H
6.3
24.0
|
L
H
6.3
24.0
|
L
H
6.3
24.0
|
| Ocular Therapeutix Inc |
|
2,398.9
|
11.3
|
L
 -1.1%
H
11.1
11.6
|
L
 -4.7%
H
10.9
12.0
|
L
 -29.4%
H
10.9
16.1
|
L
 -5.7%
H
10.3
16.4
|
L
 26.9%
H
5.8
16.4
|
L
 212.8%
H
2
16.4
|
L
 -49.1%
H
2
23.7
|
L
 51.3%
H
2
24.3
|
| Opus Genetics Inc |
|
133.1
|
1.9
|
L
 -3.5%
H
1.9
2.0
|
L
 -9.0%
H
1.9
2.2
|
L
 -19.3%
H
1.9
2.6
|
L
 -3.0%
H
1.7
2.6
|
L
 29.5%
H
0.7
2.6
|
L
 -43.2%
H
0.7
6.6
|
L
 -73.2%
H
0.7
13.8
|
L
 -98.8%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
213.3
|
7.4
|
L
 -0.8%
H
7.0
7.5
|
L
 3.9%
H
7.0
7.5
|
L
 44.5%
H
4.7
7.5
|
L
 95.8%
H
3.6
8.5
|
L
 233.6%
H
1.9
8.5
|
L
 -2.1%
H
1.9
10
|
L
 -87.6%
H
1.9
131.4
|
L
 -94.7%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
103.8
|
2.8
|
L
 19.0%
H
2.5
2.8
|
L
 23.8%
H
2.1
2.8
|
L
 40.1%
H
1.8
2.8
|
L
 31.4%
H
1.7
2.9
|
L
 115.6%
H
0.9
3.4
|
L
 40.1%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
2,250.9
|
28.1
|
L
 9.8%
H
25.8
28.2
|
L
 11.1%
H
23.9
28.2
|
L
 5.6%
H
23.9
36.3
|
L
 162.9%
H
6.7
36.3
|
L
 388.4%
H
2.9
36.3
|
L
 800%
H
2.9
36.3
|
L
 -33.5%
H
2
54.9
|
L
H
2
60.3
|
| Omeros Corp |
|
885.5
|
12.5
|
L
 -7.1%
H
12.5
14.3
|
L
 -23.8%
H
12.5
16.4
|
L
 8.9%
H
8.3
17.7
|
L
 173.9%
H
4.1
17.7
|
L
 26.3%
H
3.0
17.7
|
L
 335.2%
H
0.9
17.7
|
L
 -22.0%
H
0.9
23.9
|
L
 8.6%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
104.4
|
1.0
|
L
 -2.0%
H
1.0
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.1
|
L
 -21.8%
H
0.9
1.3
|
L
 11.5%
H
0.3
1.5
|
L
 -39.8%
H
0.3
3.4
|
L
 -62.3%
H
0.3
4.8
|
L
 -63.5%
H
0.3
8.5
|
| Traws Pharma Inc |
|
10.7
|
1.3
|
L
 -5.0%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 -44.9%
H
1.1
2.6
|
L
 -57.2%
H
1.1
3.3
|
L
 -83.8%
H
1.0
9.3
|
L
 -92.4%
H
1.0
37.3
|
L
 -99.4%
H
1.0
723.8
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
5.0
|
1.9
|
L
 -7.7%
H
1.9
2.2
|
L
 2.1%
H
1.9
2.3
|
L
 -18.6%
H
1.7
2.4
|
L
 -42.2%
H
1.7
3.4
|
L
 -62.9%
H
0.3
22.0
|
L
 -89.2%
H
0.3
40.8
|
L
 -98.7%
H
0.3
287.0
|
L
 -99.6%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
891.1
|
9.2
|
L
 8.3%
H
8.5
9.2
|
L
 12%
H
7.8
9.2
|
L
 -9.8%
H
7.8
10.3
|
L
 -35.0%
H
7.8
14.2
|
L
 7.7%
H
3.9
14.9
|
L
 62.8%
H
3.9
16.7
|
L
 -70.7%
H
2.4
39.5
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
136.5
|
3.4
|
L
 -1.4%
H
3.3
3.5
|
L
 17.9%
H
2.9
3.5
|
L
 28.0%
H
2.7
3.5
|
L
 44.7%
H
2.1
3.5
|
L
 44.1%
H
1.8
3.5
|
L
 -64.1%
H
1.7
11.5
|
L
 -23.8%
H
1.7
31.5
|
L
 -52.0%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
37.8
|
0.6
|
L
 -1.7%
H
0.6
0.7
|
L
 -10.6%
H
0.5
0.7
|
L
 -71.6%
H
0.5
2.5
|
L
 -52.0%
H
0.5
2.5
|
L
 -72.9%
H
0.5
3.0
|
L
 -99.9%
H
0.5
812
|
L
 -99.9%
H
0.5
1704
|
L
H
0.5
17568
|
| Ovid Therapeutics Inc |
|
118.9
|
1.7
|
L
 -3.5%
H
1.7
1.8
|
L
 -5.1%
H
1.6
1.9
|
L
 6.4%
H
1.3
1.9
|
L
 -4.0%
H
1.2
1.9
|
L
 83.5%
H
0.2
2.0
|
L
 -16.9%
H
0.2
4.1
|
L
 -31.0%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,598.6
|
39.4
|
L
 -0.7%
H
39.2
40.2
|
L
 5.7%
H
36.8
40.4
|
L
 3.0%
H
36.1
41.6
|
L
 6.1%
H
35.8
46.4
|
L
 83.6%
H
16.2
46.4
|
L
 188.3%
H
9.4
46.4
|
L
 88.8%
H
9.4
46.4
|
L
 34.9%
H
9.4
54.6
|
| Palisade Bio Inc |
|
296.9
|
2.0
|
L
 4.7%
H
1.9
2.0
|
L
 -20.4%
H
1.8
2.6
|
L
 4.7%
H
1.7
2.6
|
L
 -5.2%
H
1.5
2.6
|
L
 -1%
H
0.5
2.6
|
L
 -95.3%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1275300
|
| Passage Bio Inc |
|
63.1
|
19.9
|
L
 8.3%
H
17.4
20
|
L
 69.8%
H
13.3
20
|
L
 90.9%
H
8.6
20
|
L
 128.7%
H
6.2
20
|
L
 50.6%
H
5.1
20
|
L
 -46.1%
H
5.1
37.8
|
L
 -96.4%
H
5.1
617.4
|
L
H
5.1
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.6
|
2.3
|
L
 13.1%
H
2.2
3.0
|
L
 15.4%
H
2.0
3.0
|
L
 -45.8%
H
1.4
4.7
|
L
 -97.8%
H
1.4
124
|
L
 -98.3%
H
1.4
150
|
L
 -99.5%
H
1.4
670
|
L
 -99.9%
H
1.4
5160
|
L
H
1.4
12200
|
| Puma biotech Inc |
|
307.9
|
6.1
|
L
 -1.5%
H
6.1
6.3
|
L
 5.9%
H
5.7
6.3
|
L
 10.7%
H
5.4
6.3
|
L
 17.3%
H
4.6
6.3
|
L
 72.1%
H
2.6
6.3
|
L
 32.5%
H
2.1
7.7
|
L
 -46.4%
H
1.6
14.1
|
L
 -89.6%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
967.1
|
23.5
|
L
 -9.6%
H
22.5
24.9
|
L
 -3.8%
H
22.5
26.5
|
L
 -5.0%
H
22.5
27.2
|
L
 2.0%
H
19.8
27.2
|
L
 26.6%
H
19.8
27.6
|
L
 -36.1%
H
11.2
48.6
|
L
 -66.5%
H
11.2
82.2
|
L
 -65.2%
H
11.2
82.2
|
| Processa Pharma Inc |
|
7.6
|
3.4
|
L
 -2.9%
H
3.3
3.5
|
L
 14.7%
H
3
3.6
|
L
 -55.9%
H
2.8
8.9
|
L
 -65.8%
H
2.8
11.1
|
L
 -84.4%
H
2.8
22.8
|
L
 -99.4%
H
2.8
725
|
L
 -99.9%
H
2.8
7120
|
L
 -100.0%
H
2.8
17937.5
|
| Vaxcyte Inc |
|
6,028.2
|
46.1
|
L
 1.6%
H
45.7
47.7
|
L
 -0.9%
H
43.9
47.7
|
L
 2.9%
H
42.4
48.7
|
L
 9.7%
H
39.9
50.3
|
L
 -43.2%
H
27.7
93.8
|
L
 0.3%
H
27.7
121.1
|
L
 75.7%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
58.6
|
1.1
|
L
 8.1%
H
1.0
1.2
|
L
 28.9%
H
0.8
1.2
|
L
 0.9%
H
0.8
1.2
|
L
 8.1%
H
0.7
1.2
|
L
 -31.9%
H
0.7
2.2
|
L
 -90.3%
H
0.7
11.3
|
L
 -55.2%
H
0.7
17.9
|
L
 -99.6%
H
0.6
355.4
|
| PepGen Inc |
|
444.8
|
6.5
|
L
 -4.0%
H
6.4
7.0
|
L
 -9.8%
H
6.4
7.5
|
L
 13.5%
H
5.1
7.8
|
L
 28.6%
H
4.1
7.8
|
L
 87.5%
H
0.9
7.8
|
L
 -55.5%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,624.1
|
4.6
|
L
 -0.4%
H
4.6
4.8
|
L
 7.2%
H
4.0
5.0
|
L
 30.8%
H
3.4
5.0
|
L
 43.9%
H
3.0
5.2
|
L
 289.0%
H
1.1
5.2
|
L
 194.2%
H
0.7
5.2
|
L
 -50.6%
H
0.7
9.9
|
L
 -82.1%
H
0.7
40.2
|
| Phathom Pharma Inc |
|
1,171.8
|
15.0
|
L
 -3.7%
H
14.8
15.7
|
L
 -4.4%
H
14.8
18.1
|
L
 5.7%
H
14.1
18.3
|
L
 29.0%
H
11.3
18.3
|
L
 116.1%
H
2.2
18.3
|
L
 93.3%
H
2.2
19.7
|
L
 -57.5%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
12.5
|
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 6.4%
H
1.1
1.2
|
L
 0.9%
H
1
1.2
|
L
 -50.9%
H
1
4.2
|
L
 -31.4%
H
1.0
9.8
|
L
 -98.3%
H
0.6
110.4
|
L
 -99.6%
H
0.6
470.9
|
L
 -100.0%
H
0.6
230115.6
|
| Pharvaris NV |
|
1,681.8
|
25.9
|
L
 3.6%
H
24.9
27.1
|
L
 -2.2%
H
23.6
27.1
|
L
 7.7%
H
23.2
28.4
|
L
 13.4%
H
20.7
29.8
|
L
 39.6%
H
11.5
29.8
|
L
 115.8%
H
6.0
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
81.1
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 5.6%
H
1.2
1.4
|
L
 4.8%
H
1.2
1.4
|
L
 -14.3%
H
1.2
2.0
|
L
 -89.5%
H
1.1
12.8
|
L
 -93.2%
H
1.1
36.6
|
L
 -95.2%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
28.2
|
3.1
|
L
 1.3%
H
3
3.1
|
L
 2.0%
H
2.9
3.3
|
L
 -11.3%
H
2.8
3.9
|
L
 -31.9%
H
2.8
4.9
|
L
 -31.5%
H
2.8
7.1
|
L
 -63.7%
H
0.7
11.6
|
L
 -94.9%
H
0.7
79.1
|
L
 -96.2%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
8.9
|
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
 18.9%
H
0.7
1.0
|
L
 -20.7%
H
0.7
1.1
|
L
 -12.9%
H
0.6
1.5
|
L
 -47.0%
H
0.6
1.9
|
L
 -70.6%
H
0.6
3.2
|
L
 -96.8%
H
0.6
55.5
|
L
 -99.2%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
7,905.6
|
288.5
|
L
 -2.0%
H
286.0
305.2
|
L
 0.7%
H
268.8
305.2
|
L
 11.8%
H
251
317.7
|
L
 426.8%
H
50.6
317.7
|
L
 291.5%
H
26.7
317.7
|
L
 701.3%
H
11.9
317.7
|
L
 -67.4%
H
11.9
905.9
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
3.3
|
0.9
|
L
H
0.8
0.9
|
L
 21.4%
H
0.7
0.9
|
L
 -8.6%
H
0.6
1.1
|
L
 -40.6%
H
0.6
1.5
|
L
 -73.2%
H
0.6
6.7
|
L
 -96.9%
H
0.2
158.5
|
L
 -99.7%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
165.3
|
2.6
|
L
 -4.7%
H
2.6
2.8
|
L
 -3.7%
H
2.4
3.0
|
L
 54.7%
H
1.6
3
|
L
 87.9%
H
1.2
4.2
|
L
 130.7%
H
0.6
4.2
|
L
 -43.3%
H
0.6
8.6
|
L
 -96.0%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
711.2
|
3.9
|
L
 0.5%
H
3.9
4.1
|
L
 11.6%
H
3.4
4.2
|
L
 -6.0%
H
3.3
4.4
|
L
 -36.8%
H
3.2
6.7
|
L
 25.1%
H
1.1
6.9
|
L
 -75.8%
H
1.1
21.5
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
331.2
|
2.3
|
L
 -0.9%
H
2.3
2.4
|
L
 4.9%
H
2.1
2.5
|
L
 5.9%
H
2.1
2.6
|
L
 -29.1%
H
2.0
3.5
|
L
 41.0%
H
0.5
7.1
|
L
 -66.6%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
186.5
|
1.8
|
L
 -15.7%
H
1.7
2.1
|
L
 -11.1%
H
1.7
2.3
|
L
 -23.7%
H
1.7
2.5
|
L
 -29.2%
H
1.7
3.1
|
L
 -32.4%
H
1.1
3.1
|
L
 -45.5%
H
1.1
4.6
|
L
 -58.6%
H
0.5
9.5
|
L
 -73.7%
H
0.5
24
|
| Prothena Corporation plc |
|
494.7
|
9.2
|
L
 1.6%
H
9.1
9.3
|
L
 -0.1%
H
8.9
9.5
|
L
 -11.0%
H
8.9
10.5
|
L
 -10.8%
H
8.9
11.7
|
L
 -34.3%
H
4.3
16.7
|
L
 -82.5%
H
4.3
79.7
|
L
 -28.3%
H
4.3
79.8
|
L
 -82.9%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
7.4
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 18.4%
H
0.7
1.1
|
L
 -46.4%
H
0.6
1.7
|
L
 -89.2%
H
0.6
8.0
|
L
 -80.9%
H
0.6
15.8
|
L
 -99.2%
H
0.6
127
|
L
 -99.7%
H
0.6
899.5
|
L
 -99.7%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
77.0
|
0.6
|
L
 -3.5%
H
0.6
0.6
|
L
H
0.5
0.6
|
L
 -16.4%
H
0.5
0.8
|
L
 -22.2%
H
0.5
0.8
|
L
 -53.3%
H
0.2
2.3
|
L
 -89.9%
H
0.2
7.2
|
L
 -98.3%
H
0.2
81.3
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
6,224.8
|
77.5
|
L
 0.9%
H
77.0
79.9
|
L
 1.0%
H
74.2
79.9
|
L
 5.5%
H
73.4
80.2
|
L
 17.5%
H
64.4
87.5
|
L
 72.1%
H
36.0
87.5
|
L
 86.4%
H
17.5
87.5
|
L
 14.7%
H
17.5
87.5
|
L
 194.6%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
5,015.0
|
80.2
|
L
 0.0%
H
79.4
81.4
|
L
 -8.0%
H
79.2
87.5
|
L
 -9.4%
H
79.2
96.5
|
L
 19.7%
H
65.8
96.5
|
L
 113.2%
H
33.7
96.5
|
L
 607.4%
H
11.2
96.5
|
L
 288.5%
H
6.9
96.5
|
L
H
4.5
96.5
|
| Pulmatrix Inc |
|
8.6
|
2.4
|
L
 0.4%
H
2.4
2.4
|
L
 4.4%
H
2.3
2.4
|
L
 -46%
H
2.2
4.9
|
L
 -50.7%
H
2.2
5.2
|
L
 -60.6%
H
2.2
10.4
|
L
 -40.1%
H
1.6
10.4
|
L
 -91.1%
H
1.6
60.8
|
L
 -99.7%
H
1.6
1396
|
| Polypid Ltd |
|
77.2
|
4.6
|
L
 -0.2%
H
4.6
4.9
|
L
 6.7%
H
4.3
5.0
|
L
 16.6%
H
3.9
5.0
|
L
 39.8%
H
3.1
5.0
|
L
 55.2%
H
2.3
5.0
|
L
 -80.4%
H
2.3
38.7
|
L
 -98.5%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
109.6
|
1.8
|
L
 21.4%
H
1.5
1.8
|
L
 53.0%
H
1.1
1.8
|
L
 -59.1%
H
1.0
4.6
|
L
 -54.1%
H
1.0
5.6
|
L
 9.3%
H
0.8
5.6
|
L
 19.7%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,303.5
|
18.7
|
L
 4.6%
H
17.7
18.8
|
L
 9.2%
H
16.6
18.8
|
L
 10.0%
H
16.2
18.8
|
L
 28.2%
H
12.7
18.8
|
L
 91.9%
H
7.5
18.8
|
L
 58.0%
H
6.7
18.8
|
L
 27.7%
H
6.1
18.8
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
6.2
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 4.6%
H
0.7
0.7
|
L
 -15.9%
H
0.6
0.9
|
L
 11.3%
H
0.6
1.4
|
L
 -81.8%
H
0.5
4.0
|
L
 -97.7%
H
0.5
47.4
|
L
 -99.1%
H
0.5
145
|
L
 -99.9%
H
0.5
1390
|
| PureTech Health Plc ADR |
|
425.4
|
17.6
|
L
 0.1%
H
17.2
17.6
|
L
 5.8%
H
16.7
17.7
|
L
 4.1%
H
16.4
17.9
|
L
 -2.2%
H
15.5
18.9
|
L
 0.3%
H
13.3
20
|
L
 -44.8%
H
13.3
38.5
|
L
 -69.1%
H
13.3
65.9
|
L
H
13.3
65.9
|
| AIxCrypto Holdings Inc |
|
13.2
|
2.6
|
L
H
2.5
2.6
|
L
 6.7%
H
2.5
2.9
|
L
 1.2%
H
2.2
3.0
|
L
 -41.8%
H
2.2
6.0
|
L
 -38.6%
H
1.6
8.8
|
L
 -96.0%
H
0.1
79.5
|
L
 -99.8%
H
0.1
2217
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
798.5
|
4.0
|
L
 3.9%
H
3.6
4.0
|
L
 11.2%
H
3.3
4.3
|
L
 -36.8%
H
3.3
6.4
|
L
 -59.1%
H
3.3
10.1
|
L
 -66.7%
H
3.3
17.2
|
L
 -14.4%
H
1.8
17.2
|
L
 298%
H
1
110
|
L
H
1
110
|
| Quince Therapeutics Inc |
|
149.8
|
2.7
|
L
 0.4%
H
2.6
2.8
|
L
 -10.3%
H
2.6
3.1
|
L
 -30.3%
H
2.6
4.6
|
L
 31.9%
H
1.4
4.6
|
L
 43.1%
H
0.7
4.6
|
L
 284.3%
H
0.5
4.6
|
L
 -91.2%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
1,577.2
|
25.3
|
L
 9.4%
H
24.8
28.8
|
L
 8.3%
H
22.1
28.8
|
L
 21.9%
H
19.3
28.8
|
L
 -60.2%
H
19.3
71.5
|
L
 55.2%
H
7.8
71.5
|
L
 20.2%
H
3.7
71.5
|
L
 -38.2%
H
3.7
71.5
|
L
 39.2%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
10.2
|
12.2
|
L
 -7.2%
H
11.9
13.3
|
L
 -13.3%
H
11.9
14.5
|
L
 -1.6%
H
9.7
14.9
|
L
 49.6%
H
8.1
41.8
|
L
 -97.2%
H
5.1
471.1
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
136.8
|
3.8
|
L
 -4.1%
H
3.8
4.1
|
L
 -24.8%
H
3.6
5.1
|
L
 -32.4%
H
3.6
8.5
|
L
 -31.9%
H
3.6
8.5
|
L
 210.7%
H
1.4
9.2
|
L
 -67.6%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
136.6
|
1.4
|
L
 0.7%
H
1.4
1.4
|
L
 2.9%
H
1.3
1.5
|
L
 -9.7%
H
1.3
1.6
|
L
 191.7%
H
0.4
3.9
|
L
 2.9%
H
0.4
3.9
|
L
 -78.3%
H
0.4
8.8
|
L
 -99.3%
H
0.4
36.3
|
L
H
0.4
224.5
|
| RAPT Therapeutics Inc |
|
931.6
|
33.6
|
L
 7.8%
H
32.1
33.7
|
L
 5.6%
H
29.8
33.7
|
L
 -4.8%
H
29.8
38.5
|
L
 12.0%
H
24.3
42.4
|
L
 189.8%
H
5.7
42.4
|
L
 -80.1%
H
5.7
251.6
|
L
 -80.1%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
2,171.7
|
22.5
|
L
 -3.0%
H
22.5
23.9
|
L
 -4.6%
H
22.1
25.1
|
L
 -38.0%
H
18.4
36.8
|
L
 -28.9%
H
18.4
39.9
|
L
 -48.4%
H
18.4
46.5
|
L
 -44.6%
H
18.4
60.4
|
L
 -85.1%
H
18.4
175
|
L
 -74.0%
H
18.4
179.7
|
| Rocket Pharmaceuticals Inc |
|
403.7
|
3.7
|
L
 -3.9%
H
3.7
4
|
L
 7.8%
H
3.5
4.1
|
L
 11.0%
H
3.2
4.1
|
L
 1.6%
H
2.8
4.5
|
L
 -68.4%
H
2.2
11.7
|
L
 -80.2%
H
2.2
32.5
|
L
 -93.4%
H
2.2
67.5
|
L
 -89.9%
H
2.2
67.5
|
| Regeneron Pharma |
|
83,717.0
|
796.6
|
L
 -0.6%
H
790.9
821.1
|
L
 2.6%
H
753.2
821.1
|
L
 15.0%
H
692.5
821.1
|
L
 39.8%
H
541
821.1
|
L
 8.6%
H
476.5
821.1
|
L
 17.1%
H
476.5
1211.2
|
L
 59.7%
H
441
1211.2
|
L
 62.0%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
629.9
|
8.0
|
L
 -2.4%
H
8.0
8.5
|
L
 -9.8%
H
8.0
9.4
|
L
 -22.0%
H
8.0
10.4
|
L
 73.4%
H
4.3
11.3
|
L
 -30.4%
H
2.7
14.8
|
L
 -68.5%
H
2.7
29.5
|
L
 -81.2%
H
2.7
46.6
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
5.3
|
0.9
|
L
H
0.9
0.9
|
L
 11.1%
H
0.8
0.9
|
L
 -15.1%
H
0.8
1.2
|
L
 -38.8%
H
0.8
1.5
|
L
 -96.8%
H
0.7
27.7
|
L
 -100.0%
H
0.7
16405.2
|
L
 -100.0%
H
0.7
569016
|
L
H
0.7
569016
|
| Regencell Bioscience Holdings Ltd |
|
22,642.6
|
45.8
|
L
 10.6%
H
36
51.0
|
L
 122.9%
H
23.3
69
|
L
 175.8%
H
16.1
69
|
L
 148.3%
H
10.3
69
|
L
 32607.1%
H
0.1
83.6
|
L
 6005.3%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
9,390.4
|
166.8
|
L
 0.2%
H
164.3
169.6
|
L
 1.5%
H
164.2
175.8
|
L
 3.8%
H
156.0
175.8
|
L
 12.1%
H
139.4
175.8
|
L
 8.6%
H
103.0
182.5
|
L
 5.0%
H
103.0
211.1
|
L
 -19.9%
H
103.0
327.3
|
L
 595.7%
H
20.1
327.3
|
| Regenxbio Inc |
|
738.6
|
14.6
|
L
 -2.7%
H
14.6
15.6
|
L
 7.5%
H
12.9
15.8
|
L
 14.7%
H
12.6
15.8
|
L
 19.9%
H
10.7
15.8
|
L
 76%
H
5.0
15.8
|
L
 -33.3%
H
5.0
28.8
|
L
 -68.9%
H
5.0
50.3
|
L
 5.9%
H
5.0
85.1
|
| Rigel Pharma |
|
741.3
|
40.8
|
L
 -8.2%
H
40.8
45.3
|
L
 -2.4%
H
40.5
49.1
|
L
 -3.5%
H
40.5
49.1
|
L
 43.8%
H
26.4
52.2
|
L
 143.5%
H
15.5
52.2
|
L
 2796.5%
H
0.7
52.2
|
L
 1040.8%
H
0.6
52.2
|
L
 1374.4%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
1,384.8
|
8.0
|
L
 -0.1%
H
7.9
8.2
|
L
 -2.3%
H
7.7
8.7
|
L
 5.4%
H
7.4
9.0
|
L
 17.9%
H
5.9
9.0
|
L
 65.4%
H
1.8
9.0
|
L
 -48.7%
H
1.8
23.2
|
L
 -80.4%
H
1.8
64.4
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
316.1
|
4.3
|
L
 -2.7%
H
4.3
4.5
|
L
 -1.4%
H
4.0
4.5
|
L
 4.1%
H
4.0
5.0
|
L
 95.9%
H
1.8
5.1
|
L
 857.8%
H
0.2
5.1
|
L
 27.1%
H
0.2
7.2
|
L
 -87.8%
H
0.2
40
|
L
 -54.5%
H
0.2
54
|
| Avidity Biosciences Inc |
|
10,904.4
|
72.4
|
L
H
72.3
72.4
|
L
 0.4%
H
72
72.5
|
L
 1.5%
H
71.3
72.6
|
L
 42.5%
H
46.1
72.6
|
L
 141.8%
H
21.5
72.6
|
L
 288.5%
H
4.8
72.6
|
L
 157.1%
H
4.8
72.6
|
L
H
4.8
72.6
|
| TransCode Therapeutics Inc |
|
7.3
|
8.0
|
L
 1.0%
H
7.6
8.1
|
L
 8.2%
H
6.5
8.2
|
L
 -4.8%
H
6.1
11.3
|
L
 -45.8%
H
6.1
15.9
|
L
 -91.7%
H
6.1
468.4
|
L
 -100.0%
H
6.1
790944
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| RenovoRx Inc |
|
41.0
|
1.1
|
L
 -2.6%
H
1.1
1.3
|
L
 33.3%
H
0.9
1.3
|
L
 16.7%
H
0.8
1.3
|
L
H
0.7
1.3
|
L
 -15.2%
H
0.7
1.7
|
L
 -65.6%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
15,286.9
|
22.0
|
L
 0.9%
H
21.9
22.5
|
L
 0.2%
H
20.8
22.5
|
L
 7.6%
H
20.1
23.5
|
L
 36.4%
H
15.9
23.5
|
L
 99.5%
H
8.7
23.5
|
L
 133.3%
H
6.6
23.5
|
L
 115.9%
H
2.5
23.5
|
L
H
2.5
23.5
|
| Royalty Pharma PLC (Class A) |
|
17,162.5
|
40.2
|
L
 -0.2%
H
40.1
41.0
|
L
 3.4%
H
38.5
41.7
|
L
 5.5%
H
37.8
41.7
|
L
 11.2%
H
35.2
41.7
|
L
 53.3%
H
27.5
41.7
|
L
 2.5%
H
24.1
41.7
|
L
 -21.7%
H
24.1
53.2
|
L
H
24.1
56.5
|
| Repare Therapeutics Inc |
|
109.5
|
2.5
|
L
 0.4%
H
2.5
2.6
|
L
 -1.2%
H
2.5
2.6
|
L
 17.6%
H
2.1
2.7
|
L
 38.8%
H
1.7
2.7
|
L
 98.4%
H
0.9
2.7
|
L
 -81.1%
H
0.9
14.0
|
L
 -94.0%
H
0.9
46.0
|
L
H
0.9
46.4
|
| Revolution Medicines Inc |
|
22,935.5
|
118.6
|
L
 10.5%
H
109.8
121.6
|
L
 50.1%
H
76.3
121.6
|
L
 52.5%
H
73
121.6
|
L
 149.1%
H
47.3
121.6
|
L
 167.1%
H
29.2
121.6
|
L
 435.9%
H
15.5
121.6
|
L
 194.2%
H
14.1
121.6
|
L
H
14.1
121.6
|
| Reviva Pharma Holdings Inc |
|
39.7
|
0.3
|
L
 -8.1%
H
0.3
0.4
|
L
 9.7%
H
0.3
0.4
|
L
 -50.7%
H
0.3
0.8
|
L
 -56.4%
H
0.3
0.8
|
L
 -81.8%
H
0.3
2.2
|
L
 -91.0%
H
0.3
9.3
|
L
 -96.4%
H
0.3
9.6
|
L
H
0.3
15.1
|
| Recursion Pharma Inc (Class A) |
|
2,425.3
|
4.7
|
L
 -0.9%
H
4.6
4.8
|
L
 11.0%
H
4.3
5
|
L
 -2.3%
H
4.1
5.0
|
L
 -21.2%
H
3.8
7.2
|
L
 -35.8%
H
3.8
12.4
|
L
 -38.0%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharma Inc |
|
6,741.7
|
101.0
|
L
 3.7%
H
96.7
103.2
|
L
 -3.8%
H
96.2
104.7
|
L
 0.3%
H
96.2
122.2
|
L
 0.8%
H
95.3
122.2
|
L
 74.6%
H
45.9
122.2
|
L
 217.6%
H
15.5
122.2
|
L
 198.2%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
243.9
|
2.6
|
L
 11.0%
H
2.3
2.7
|
L
 21.8%
H
1.9
2.7
|
L
 -73.3%
H
1.1
11.2
|
L
 -70.2%
H
1.1
11.5
|
L
 -49.5%
H
1.1
11.5
|
L
 33.5%
H
0.7
11.5
|
L
 -79.8%
H
0.7
17.5
|
L
 -96.2%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
6.5
|
1.3
|
L
 -5.2%
H
1.3
1.4
|
L
 23.3%
H
1.2
1.4
|
L
 5.8%
H
0.9
1.4
|
L
 -30.6%
H
0.9
2.1
|
L
 -79.7%
H
0.9
6.8
|
L
 -99.2%
H
0.9
287.5
|
L
 -100.0%
H
0.9
11520
|
L
 -100.0%
H
0.9
16540
|
| SAB Biotherapeutics Inc |
|
175.2
|
3.7
|
L
 -4.7%
H
3.6
3.9
|
L
 -2.4%
H
3.6
4.2
|
L
 -2.1%
H
3.5
4.2
|
L
 47.2%
H
2.1
4.2
|
L
 -8.7%
H
1
6.6
|
L
 441.2%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
1,214.6
|
4.6
|
L
 0.9%
H
4.4
4.7
|
L
 8.8%
H
4.0
4.9
|
L
 4.8%
H
3.9
5.4
|
L
 2.5%
H
3.2
6.6
|
L
 6.1%
H
1.3
6.6
|
L
 21.9%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
101.4
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 0.5%
H
2.1
2.3
|
L
 -35.2%
H
2.0
3.3
|
L
 -49.9%
H
2.0
5.0
|
L
 -25.5%
H
1.2
5.0
|
L
 -92.7%
H
1.2
42.2
|
L
 -74.9%
H
1.2
146.2
|
L
 -82.9%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
6.5
|
1.3
|
L
 -2.9%
H
1.3
1.4
|
L
 3.9%
H
1.2
1.4
|
L
 -7.6%
H
1.2
1.5
|
L
 -20.4%
H
1.2
2.4
|
L
 -55.2%
H
1.2
3.9
|
L
 -98.1%
H
0.1
140
|
L
 -99.6%
H
0.1
6280
|
L
 -100.0%
H
0.1
280000
|
| Scilex Holding Co |
|
90.0
|
12.8
|
L
 -3.7%
H
12.8
13.8
|
L
 -2.2%
H
12.8
14.1
|
L
 -27.7%
H
11.8
18.2
|
L
 -27.6%
H
11.8
27
|
L
 2744.4%
H
0.2
34.3
|
L
 118.1%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
28.1
|
0.7
|
L
H
0.7
0.7
|
L
 4.7%
H
0.6
0.7
|
L
 4.7%
H
0.6
0.7
|
L
 -15.2%
H
0.6
0.9
|
L
 -45.5%
H
0.6
1.3
|
L
 -59.9%
H
0.6
3.9
|
L
 -91.4%
H
0.6
10.3
|
L
 -98.7%
H
0.6
55.6
|
| Seer Inc (Class A) |
|
109.7
|
2.0
|
L
 4.3%
H
1.9
2.0
|
L
 7.1%
H
1.8
2.0
|
L
 6.0%
H
1.8
2.0
|
L
 -15.6%
H
1.8
2.4
|
L
 -19.1%
H
1.6
2.4
|
L
 -61.3%
H
1.5
6.2
|
L
 -96.9%
H
1.5
86.6
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,269.8
|
8.2
|
L
 1.0%
H
7.7
8.3
|
L
 21.3%
H
6.6
8.3
|
L
 3.8%
H
6.4
9.2
|
L
 -18.8%
H
6.0
10.3
|
L
 -20.1%
H
6.0
15.6
|
L
 -20.1%
H
6.0
15.6
|
L
 -20.1%
H
6.0
15.6
|
L
 -20.1%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
148.1
|
0.4
|
L
 -2.2%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -12%
H
0.4
0.5
|
L
 -40.5%
H
0.4
0.8
|
L
 -63.9%
H
0.4
1.4
|
L
 -86.0%
H
0.3
3.8
|
L
 -97.4%
H
0.3
17.0
|
L
 -94.1%
H
0.3
27.5
|
| Shuttle Pharma Holdings Inc |
|
3.7
|
1.9
|
L
 7.2%
H
1.9
2.7
|
L
 6.6%
H
1.8
2.7
|
L
 6.6%
H
1.4
2.7
|
L
 -59.5%
H
1.3
5.6
|
L
 -91.0%
H
1.3
25.3
|
L
 -99.4%
H
1.3
574
|
L
H
1.3
25252
|
L
H
1.3
25252
|
| SIGA Tech Inc |
|
473.4
|
6.6
|
L
 -2.4%
H
6.6
6.8
|
L
 5.4%
H
6.3
6.9
|
L
 5.8%
H
6.1
6.9
|
L
 -21.7%
H
5.7
8.5
|
L
 5.3%
H
5.0
9.6
|
L
 -9.0%
H
4.2
12.8
|
L
 -13.6%
H
4.2
27.0
|
L
 916.9%
H
0.4
27.0
|
| SILO Pharma Inc |
|
5.2
|
0.4
|
L
H
0.4
0.4
|
L
 14.7%
H
0.3
0.4
|
L
 -11.4%
H
0.3
0.5
|
L
 -40.9%
H
0.3
0.7
|
L
 -77.2%
H
0.3
2.2
|
L
 -86.9%
H
0.3
4.5
|
L
 -97.8%
H
0.3
496
|
L
 -99.2%
H
0.3
496
|
| Solid Biosciences Inc |
|
412.1
|
5.3
|
L
 -0.4%
H
5.2
5.5
|
L
 -2.9%
H
5.2
5.8
|
L
 -8%
H
5.2
6.2
|
L
 -17.3%
H
3.8
6.5
|
L
 31.3%
H
2.4
7.4
|
L
 -11.8%
H
1.8
15.1
|
L
 -94.7%
H
1.8
173.7
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
161.6
|
58
|
L
 4.2%
H
53.7
59
|
L
 37.6%
H
43
59
|
L
 44.6%
H
38.3
59
|
L
 46.3%
H
28.8
59
|
L
 5125.2%
H
0.4
59
|
L
 1134.0%
H
0.3
59
|
L
 478.3%
H
0.3
59
|
L
H
0.3
59
|
| Soleno Therapeutics Inc |
|
2,309.5
|
43
|
L
 -5.5%
H
42.6
45.9
|
L
 -8.8%
H
42.6
50.9
|
L
 -14.0%
H
42.6
55.5
|
L
 -34.4%
H
41.8
72.9
|
L
 -3.4%
H
41.5
90.3
|
L
 1836.9%
H
1.8
90.3
|
L
 28.0%
H
0.9
90.3
|
L
 -64.4%
H
0.9
142.5
|
| SELLAS Life Sciences Grp Inc |
|
589.2
|
3.5
|
L
 -10.4%
H
3.2
3.7
|
L
 -20.5%
H
3.2
5.2
|
L
 82.1%
H
1.8
5.2
|
L
 82.1%
H
1.4
5.2
|
L
 264.2%
H
0.9
5.2
|
L
 27.2%
H
0.5
5.2
|
L
 -45.3%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
14,650.6
|
19.7
|
L
 4.5%
H
19.0
20.2
|
L
 12.3%
H
17.3
20.2
|
L
 15.6%
H
16.8
20.2
|
L
 -13.1%
H
15.6
25.5
|
L
 4.6%
H
15.6
36.9
|
L
 422.0%
H
1.3
36.9
|
L
 279.2%
H
0.7
36.9
|
L
 94.1%
H
0.7
36.9
|